<?xml version='1.0' encoding='UTF-8'?>
<pmc-articleset><article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="iso-abbrev">Nat Sci Sleep</journal-id>
      <journal-id journal-id-type="publisher-id">nss</journal-id>
      <journal-id journal-id-type="pmc">nss</journal-id>
      <journal-title-group>
        <journal-title>Nature and Science of Sleep</journal-title>
      </journal-title-group>
      <issn pub-type="epub">1179-1608</issn>
      <publisher>
        <publisher-name>Dove</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">34007229</article-id>
      <article-id pub-id-type="pmc">8123964</article-id>
      <article-id pub-id-type="publisher-id">275931</article-id>
      <article-id pub-id-type="doi">10.2147/NSS.S275931</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Review</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Reviewing the Clinical Implications of Treating Narcolepsy as an Autoimmune Disorder</article-title>
        <alt-title alt-title-type="running-authors">Giannoccaro et al</alt-title>
        <alt-title alt-title-type="running-title">Giannoccaro et al</alt-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Giannoccaro</surname>
            <given-names>Maria Pia</given-names>
          </name>
          <xref ref-type="aff" rid="aff0001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff0002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1815-1013</contrib-id>
          <name>
            <surname>Liguori</surname>
            <given-names>Rocco</given-names>
          </name>
          <xref ref-type="aff" rid="aff0001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff0002">
            <sup>2</sup>
          </xref>
        </contrib>
        <contrib contrib-type="author">
          <contrib-id contrib-id-type="orcid" authenticated="false">http://orcid.org/0000-0002-1051-0472</contrib-id>
          <name>
            <surname>Plazzi</surname>
            <given-names>Giuseppe</given-names>
          </name>
          <xref ref-type="aff" rid="aff0001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff0003">
            <sup>3</sup>
          </xref>
          <xref ref-type="corresp" rid="an0001"/>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Pizza</surname>
            <given-names>Fabio</given-names>
          </name>
          <xref ref-type="aff" rid="aff0001">
            <sup>1</sup>
          </xref>
          <xref ref-type="aff" rid="aff0002">
            <sup>2</sup>
          </xref>
        </contrib>
        <aff id="aff0001"><label>1</label><institution>IRCCS Istituto delle Scienze Neurologiche di Bologna, Ospedale Bellaria</institution>, <addr-line>Bologna</addr-line>, <country>Italy</country></aff>
        <aff id="aff0002"><label>2</label><institution>Department of Biomedical and Neuromotor Sciences, University of Bologna</institution>, <addr-line>Bologna</addr-line>, <country>Italy</country></aff>
        <aff id="aff0003"><label>3</label><institution>Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia</institution>, <addr-line>Modena</addr-line>, <country>Italy</country></aff>
      </contrib-group>
      <author-notes>
        <corresp id="an0001">Correspondence: Giuseppe Plazzi <institution>IRCCS Istituto delle Scienze Neurologiche di Bologna, Ospedale Bellaria</institution>, <addr-line>via Altura 3</addr-line>, <addr-line>Bologna</addr-line>, <addr-line>40139</addr-line>, <country>Italy</country><phone>Tel +39 051 4966926</phone><fax>Fax +39 051 4966176</fax> Email giuseppe.plazzi@unibo.it</corresp>
      </author-notes>
      <pub-date pub-type="epub">
        <day>11</day>
        <month>5</month>
        <year>2021</year>
      </pub-date>
      <pub-date pub-type="collection">
        <year>2021</year>
      </pub-date>
      <volume>13</volume>
      <fpage>557</fpage>
      <lpage>577</lpage>
      <history>
        <date date-type="received">
          <day>16</day>
          <month>12</month>
          <year>2020</year>
        </date>
        <date date-type="accepted">
          <day>19</day>
          <month>3</month>
          <year>2021</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>© 2021 Giannoccaro et al.</copyright-statement>
        <copyright-year>2021</copyright-year>
        <copyright-holder>Giannoccaro et al.</copyright-holder>
        <license>
          <ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbynclicense">https://creativecommons.org/licenses/by-nc/3.0/</ali:license_ref>
          <license-p>This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at <ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link> and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/3.0/">http://creativecommons.org/licenses/by-nc/3.0/</ext-link>). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (<ext-link ext-link-type="uri" xlink:href="https://www.dovepress.com/terms.php">https://www.dovepress.com/terms.php</ext-link>).</license-p>
        </license>
      </permissions>
      <abstract>
        <title>Abstract</title>
        <p><citation_analysis attribute="positive">Narcolepsy type 1 (NT1) is a lifelong sleep disorder, primarily characterized clinically by excessive daytime sleepiness and cataplexy and pathologically by the loss of hypocretinergic neurons in the lateral hypothalamus. Despite being a rare disorder, the NT1-related burden for patients and society is relevant due to the early onset and chronic nature of this condition. Although the etiology of narcolepsy is still unknown, mounting evidence supports a central role of autoimmunity. To date, no cure is available for this disorder and current treatment is symptomatic. Based on the hypothesis of the autoimmune etiology of this disease, immunotherapy could possibly represent a valid therapeutic option. However, contrasting and limited results have been provided so far. This review discusses the evidence supporting the use of immunotherapy in narcolepsy, the outcomes obtained so far, current issues and future directions.</citation_analysis></p>
      </abstract>
      <kwd-group kwd-group-type="author">
        <title>Keywords</title>
        <kwd>narcolepsy type 1</kwd>
        <kwd>immunotherapy</kwd>
        <kwd>immunomodulation</kwd>
        <kwd>intravenous immunoglobulin</kwd>
        <kwd>steroid</kwd>
        <kwd>monoclonal antibodies</kwd>
      </kwd-group>
      <counts>
        <fig-count count="1"/>
        <table-count count="9"/>
        <ref-count count="116"/>
        <page-count count="21"/>
      </counts>
    </article-meta>
  </front>
  <body>
    <sec sec-type="intro" id="s0001">
      <title>Introduction</title>
      <p><citation_analysis attribute="neither">Narcolepsy is a chronic sleep disorder, primarily associated with excessive daytime sleepiness (EDS) and cataplexy, a sudden and transient loss of muscle tone triggered mainly by intense, usually positive, emotions, during wakefulness. Other symptoms, including sleep-related hallucinations, sleep paralyses, and fragmented nocturnal sleep point to an intrinsic REM sleep dysfunction (ICSD3).</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="neither"> In most cases, symptom onset is in the first two decades of life, with up to 65% of the cases presenting before the age of 20 years.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0002" ref-type="bibr">2</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0003" ref-type="bibr">3</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">According to the American Academy of Sleep Medicine (AASM),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0001" ref-type="bibr">1</xref></citation_analysis><citation_analysis attribute="positive"> two distinct subtypes are identified, Narcolepsy type 1 (NT1) and Narcolepsy type 2 (NT2). NT1 results from the loss of hypothalamic hypocretin (orexin)-producing neurons as documented by reduced or undetectable levels of hypocretin-1 (hcrt-1) in the cerebrospinal fluid (CSF) and is clinically marked by cataplexy, whereas NT2 is characterized by normal CSF hcrt-1 concentration and absence of cataplexy. The CSF hcrt-1 deficiency observed in NT1 is due to the destruction of a small group of hypocretin secreting neurons in the lateral hypothalamus.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither"> In NT2, a less severe loss of these neurons or an altered hypocretin receptor signalling</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0005" ref-type="bibr">5</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0006" ref-type="bibr">6</xref></citation_analysis><citation_analysis attribute="neither"> has been postulated. About 10% of NT2 cases transform into the NT1 phenotype, indicating disease progression over time, at least in some cases.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7–10</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Narcolepsy is classified as a rare disorder with a prevalence of 20–50/100,000 individuals worldwide</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0011" ref-type="bibr">11</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0012" ref-type="bibr">12</xref></citation_analysis><citation_analysis attribute="neither"> but is however poorly and lately recognized</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0013" ref-type="bibr">13</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0014" ref-type="bibr">14</xref></citation_analysis><citation_analysis attribute="neither"> and burdened by a high socioeconomic impact. Indeed, narcolepsy patients have lower education and higher unemployment rate compared to the general population, resulting in reduced incomes and lowered life standards.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0015" ref-type="bibr">15–18</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, they present higher frequency of other medical/psychiatric comorbidities and concurrent medication usage, and reduced rates of marriage/cohabitation. Despite the availability of several symptomatic treatments,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="neither"> complete control of symptoms is only rarely achieved.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0020" ref-type="bibr">20</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0021" ref-type="bibr">21</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The necessity to find a cure for this lifelong and disabling condition has driven the investigation of new treatments targeting the underlying mechanisms of the disease. In this review, we will discuss the implications of treating narcolepsy as an autoimmune disorder, the therapeutic approaches used so far and their outcomes as well as the future directions.</citation_analysis></p>
    </sec>
    <sec id="s0002">
      <title>Evidence of Autoimmune Etiology in Narcolepsy</title>
      <p><citation_analysis attribute="neither">Autoimmune disorders are pathological conditions characterized by an aberrant immune response against “self-antigens” due to the loss of tolerance, which leads to inflammation, cell injury or dysfunction and clinical manifestations. Formal demonstration of the autoimmune nature of a disease requires several pieces of evidence.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0022" ref-type="bibr">22</xref></citation_analysis><citation_analysis attribute="positive"> Direct evidence is provided by the passive transfer of pathology by antibodies or T-cells from an affected individual to laboratory animals or to cells in culture. Indirect evidence comes from the simulation of disease in animal models either by active immunization or by manipulation of the immune system, or by isolation of self-reactive T-cells/autoantibodies from the organ targeted by the autoimmune attack. Finally, circumstantial evidence derives from different clinical observations such as: a) presence of genetic susceptibility (ie, recurrence in the same family and human leukocyte antigen (HLA) association); b) presence of antibodies in relation with a specific clinical phenotype; and c) response to immunotherapy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0023" ref-type="bibr">23</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">The loss of the hypocretin secreting cells represents the core feature of NT1. Nevertheless, the pathological mechanisms leading to the highly selective destruction of these hypothalamic cells, with sparing of the neighboring melanin-concentrating hormone neurons, are still unknown. However, the specificity of this loss itself, the strong association with the HLA DQB1*06:02</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0024" ref-type="bibr">24</xref></citation_analysis><citation_analysis attribute="positive"> and other genetically determined features of the immune system pointed towards the hypothesis of the autoimmune etiology of narcolepsy. This hypothesis was further supported by circumstantial evidence coming from epidemiological studies showing an association between NT1 and infections, which can provoke autoimmune reactions through different mechanisms such as bystander activation, molecular mimicry, superantigens and epitope spreading.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0025" ref-type="bibr">25</xref></citation_analysis><citation_analysis attribute="neither"> A questionnaire-based study revealed an increased frequency of narcolepsy among subjects diagnosed with strep throat before the age of 21</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0026" ref-type="bibr">26</xref></citation_analysis><citation_analysis attribute="neither"> and elevated streptococcal antibodies levels were found in patients’ sera taken within 3 years from disease onset compared to age-matched controls.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0027" ref-type="bibr">27</xref></citation_analysis><citation_analysis attribute="neither"> Lately, a link between narcolepsy and the influenza A virus subtype H1N1 (A/H1N1) was observed. In China, the incidence of narcolepsy increased three-fold within 6 months of the peak of the A/H1N1 influenza pandemic.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0028" ref-type="bibr">28</xref></citation_analysis><citation_analysis attribute="neither"> Furthermore, an increase in the incidence of narcolepsy was observed in subjects vaccinated with the H1N1 Pandemrix</citation_analysis><citation_analysis attribute="positive"><sup>®</sup></citation_analysis><citation_analysis attribute="neither"> vaccine.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0029" ref-type="bibr">29–33</xref></citation_analysis><citation_analysis attribute="positive"> These observations led to speculate that the autoimmune destruction of the hypocretin neurons could be triggered by molecular mimicry with H1N1 flu antigens. Indeed, a study reported the presence of hypocretin-specific CD4+ T-cells cross-reactive to H1N1 hemagglutinin (HA) protein in narcolepsy patients,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither"> although this finding was not replicated.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0035" ref-type="bibr">35</xref></citation_analysis></p>
      <p><citation_analysis attribute="neither">Indeed, HLA class II molecules, such as DQB1*06:02, are responsible for the presentation of antigenic peptides to CD4+ T-cells, possibly implying a prominent role of T-cells in the pathogenesis of narcolepsy. Subsequently, the discovery that polymorphisms in other genes involved in the immune response, such as the T-cell receptor alpha (TCRalpha)</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0036" ref-type="bibr">36</xref></citation_analysis><citation_analysis attribute="neither"> and the purinergic receptor subtype P2RY11 (P2RY11)</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0037" ref-type="bibr">37</xref></citation_analysis><citation_analysis attribute="neither"> among others,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0038" ref-type="bibr">38–40</xref></citation_analysis><citation_analysis attribute="positive"> are associated with an increased risk of developing the disease, further implicated the T-cells in its pathogenesis. Indeed, recently an increased hypocretin-specific CD4+ T-cell response was found in blood samples from 19 NT1 patients compared to controls.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41</xref></citation_analysis><citation_analysis attribute="neither"> However, unexpectedly, the majority of these cells were mainly HLA-DR- and not HLA-DQ6- restricted.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41</xref></citation_analysis><citation_analysis attribute="neither"> Another study showed the presence, in NT1 patients, of DQ0602-restricted CD4+ T-cells cross-reactive to hypocretin and the HA protein of the pandemic 2009/2010 A/H1N1 influenza virus.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0034" ref-type="bibr">34</xref></citation_analysis><citation_analysis attribute="neither"> Higher frequency of hypocretin responsive CD4+ and CD8+ T-cells was also observed in NT1 children.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0042" ref-type="bibr">42</xref></citation_analysis><citation_analysis attribute="neither"> However, it remains unclear if</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0043" ref-type="bibr">43</xref></citation_analysis><citation_analysis attribute="neither"> and how CD4+ T-cells are involved in the destruction of the hypocretin neurons. Indeed, one critical observation is that neuronal cells do not express HLA class II molecules but only class I, which are recognized by CD8+ and not CD4+ T lymphocytes. Nevertheless, a role of CD8+ T-cells is supported by the association with several HLA class I alleles</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0044" ref-type="bibr">44</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0045" ref-type="bibr">45</xref></citation_analysis><citation_analysis attribute="neither"> and by the finding, in nine NT1 patients, of mutations in P2RY11, encoding for a receptor highly expressed in cytotoxic CD8+ T lymphocytes.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0046" ref-type="bibr">46</xref></citation_analysis><citation_analysis attribute="neither"> The potential ability of CD8+ T-cells to destroy the hypocretinergic neurons has been further supported by the serendipitous pathological observation of extensive CD8+ T-cell infiltrates and gliosis in the hypothalamus of a patient with NT1 secondary to Ma2 antibody-mediated encephalitis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0047" ref-type="bibr">47</xref></citation_analysis><citation_analysis attribute="positive"> A similar proof of concept was demonstrated in a transgenic mice animal model where cytotoxic CD8+, but not CD4+, HA-reactive T-cells were able to destroy hypocretin neurons expressing HA as a neo-antigen.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0048" ref-type="bibr">48</xref></citation_analysis><citation_analysis attribute="positive"> Interestingly, a higher frequency of autoreactive CD8+ T-cells was recently documented in NT1 patients’ blood samples compared to controls.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0049" ref-type="bibr">49</xref></citation_analysis><citation_analysis attribute="neither"> Moreover, CD8+ T-cells were identified in the CSF of patient with recent onset NT2 who later on progressed into NT1 with hypocretin deficiency.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41</xref></citation_analysis><citation_analysis attribute="neither"> These observations suggest a direct involvement of CD8+ T-cells in the destruction of hypocretin neurons. Finally, it has recently been observed that NT1 patients display effector CD4+ T-cells with an unconventional profile which might have cytotoxic activity.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0050" ref-type="bibr">50</xref></citation_analysis></p>
      <p><citation_analysis attribute="positive">Although these evidence point to a T-cell-mediated process associated with narcolepsy, these findings are mainly based on blood sample studies, and the primary role of these cells is not clear yet.</citation_analysis></p>
      <p><citation_analysis attribute="neither">Since B cells are usually involved in CD4+ T-cell-mediated responses,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0051" ref-type="bibr">51</xref></citation_analysis><citation_analysis attribute="neither"> several studies investigated the presence of neuronal autoantibodies. Screening for antibodies against specific antigens including the hypocretin precursor-peptide,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0052" ref-type="bibr">52</xref></citation_analysis><citation_analysis attribute="neither"> hypocretin 1 and 2 and their receptors (HCRTR1 and 2)</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0053" ref-type="bibr">53</xref></citation_analysis><citation_analysis attribute="neither"> and other neuronal antigens in narcoleptic patients</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0054" ref-type="bibr">54–57</xref></citation_analysis><citation_analysis attribute="neither"> produced negative or indecisive results. Antibodies directed against Tribbles homologue 2 (TRIB2) were detected in 14% of narcoleptic patients but also in a small percentage (5%) of control sera,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0058" ref-type="bibr">58</xref></citation_analysis><citation_analysis attribute="neither"> a finding replicated also in other cohorts</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0059" ref-type="bibr">59</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0060" ref-type="bibr">60</xref></citation_analysis><citation_analysis attribute="neither"> but not in post-H1N1 cases.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0061" ref-type="bibr">61</xref></citation_analysis><citation_analysis attribute="neither"> TRIB2 is highly expressed in hypocretinergic neurons, but also in other cells types; moreover, it is an intracellular antigen, and as such is unlikely to play a primary role in the destruction of hypocretin-producing cells. Subsequently, HCRTR2 antibodies were found in 85% of post-Pandemrix</citation_analysis><citation_analysis attribute="positive"><sup>®</sup></citation_analysis><citation_analysis attribute="neither"> narcolepsy cases as well as in controls (35%),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0062" ref-type="bibr">62</xref></citation_analysis><citation_analysis attribute="positive"> but these findings have not been reproduced in idiopathic cases.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0063" ref-type="bibr">63</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0064" ref-type="bibr">64</xref></citation_analysis><citation_analysis attribute="neither"> Several studies showed the presence of antibodies directed against different neuronal targets in NT1 patients, but usually only in a small percentage of cases,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0065" ref-type="bibr">65</xref></citation_analysis><citation_analysis attribute="neither"> suggesting that the humoral response is not primarily relevant in the pathogenesis of the disease.</citation_analysis></p>
      <p><citation_analysis attribute="positive">Therefore, despite significant progresses, most evidence supporting the autoimmune etiology of narcolepsy is still circumstantial. According to Witebsky’s postulate,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0023" ref-type="bibr">23</xref></citation_analysis><citation_analysis attribute="positive"> definitive proof such as the passive transfer of the disease to healthy individuals by autoreactive T-cells and/or autoantibodies or the active immunization with autoantigen able to induce the disease in animal models, are still missing.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0022" ref-type="bibr">22</xref></citation_analysis></p>
    </sec>
    <sec id="s0003">
      <title>Immunotherapies</title>
      <p><citation_analysis attribute="positive">Soon after the autoimmune etiology of narcolepsy was hypothesized, the first attempts to arrest the pathogenic process using immunotherapy were made. These early attempts were based on the same approaches used for the treatment of classical neurological autoimmune disorders, and included corticosteroids, plasmapheresis (PLEX) and intravenous immunoglobulins (IVIG). These therapies indeed exert their action at multiple levels and could possibly be effective independently from the primary involvement of a humoral or cellular immune response. More recently, therapies specifically targeting B- and T- cells were attempted in limited cases, as discussed below.</citation_analysis></p>
      <sec id="s0003-s2001">
        <title>Immunotherapies with Pleiotropic Effects</title>
        <p><citation_analysis attribute="positive">Corticosteroids exert a broad range of effects on the immune system, from inflammatory cytokines synthesis inhibition to impairment of function and survival of multiple types of immune cells, including neutrophils, monocytes, macrophages and B and T lymphocytes.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0066" ref-type="bibr">66</xref></citation_analysis><citation_analysis attribute="neither"> Because of these wide effects, corticosteroids are widely employed to treat a variety of neurological inflammatory and autoimmune disorders and were therefore the first immunomodulatory treatment used in NT1 (</citation_analysis><citation_analysis attribute="positive"><xref rid="t0001" ref-type="table">Table 1</xref></citation_analysis><citation_analysis attribute="neither">). An 8-year-old boy was treated two months after the acute onset of NT1 with prednisone (1 mg/kg/day) for 3 weeks. However, no clinical improvement or modification of sleep parameters was observed.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0067" ref-type="bibr">67</xref></citation_analysis><citation_analysis attribute="positive"> Similar negative results were reported in a 29-year-old woman who received intravenous methylprednisolone (IVMP) for a transverse myelitis of possible autoimmune etiology nine years after the onset of NT1.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0068" ref-type="bibr">68</xref></citation_analysis><citation_analysis attribute="neither"> Conversely, Coelho et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0069" ref-type="bibr">69</xref></citation_analysis><citation_analysis attribute="positive"> described two men with a longstanding NT1 history, who reported the disappearance of EDS, and in one case also of cataplexy, upon prednisone treatment (40 mg/day) for other inflammatory conditions (inflammatory intestinal disease and asthma). However, these cases were not corroborated by CSF hypocretin-1 levels measurements nor the improvement was confirmed by repeated sleep studies after treatment and, in consideration of the long interval between disease onset and treatment, it is likely that the arousing effects of the steroids played a major role in the control of EDS.</citation_analysis><citation_analysis attribute="positive"><table-wrap id="t0001" orientation="portrait" position="float"><label>Table 1</label><caption><p><citation_analysis attribute="neither">Summary of NT1 Cases Treated Mainly with Steroids or PLEX</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Ref.</th><th rowspan="1" colspan="1">Study Design</th><th rowspan="1" colspan="1">Case</th><th rowspan="1" colspan="1">Age, Sex</th><th rowspan="1" colspan="1">Disease Duration</th><th rowspan="1" colspan="1">Reason for Immune Modulation</th><th rowspan="1" colspan="1">Scheme</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">Treatment Outcome</th><th rowspan="1" colspan="1">Follow-Up</th><th rowspan="1" colspan="1">Side Effects</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">[<xref rid="cit0067" ref-type="bibr">67</xref>]</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">8, M</td><td rowspan="1" colspan="1">2 months</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PO 1 mg/kg/d for 3 weeks.</td><td rowspan="1" colspan="1">ESS N/A, CPL 0,<break/>hcrt 1 &lt;40, MSLT<break/>s.l. 0.6 m, SOREMs 5</td><td rowspan="1" colspan="1">ESS unchanged, MSLT: s.l.<break/>0.0, SOREMs 4/4</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="2" colspan="1">[<xref rid="cit0070" ref-type="bibr">70</xref>]</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">10, M</td><td rowspan="1" colspan="1">3 months after CPL onset</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IVIG 1g/kg/d over 2 days</td><td rowspan="1" colspan="1">ESS N/A;<break/>CPL ≥1/d,<break/>hcrt-1&lt;40, MSLT N/A</td><td rowspan="1" colspan="1">↓ EDS<break/>↓ CPL<break/>hcrt-1 &lt;40<break/>MSLT N/A</td><td rowspan="2" colspan="1">Reappearance of symptoms after steroid suspension</td><td rowspan="1" colspan="1">Headache, fever, and flushing</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Followed by PO 1.3 mg/kg/d for 3 w and tapering</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Weight gain and acne with irritant dermatitis</td></tr><tr><td rowspan="2" colspan="1">[<xref rid="cit0069" ref-type="bibr">69</xref>]</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">22, M</td><td rowspan="1" colspan="1">9 years</td><td rowspan="1" colspan="1">Inflammatory intestinal disease</td><td rowspan="1" colspan="1">PO 40 mg/d</td><td rowspan="1" colspan="1">ESS 15, CPL frequent<break/>s.l. 4 m<break/>SOREMS 2</td><td rowspan="1" colspan="1">Symptoms disappearance with withdrawal of methylphenidate, imipramine</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">42, M</td><td rowspan="1" colspan="1">9 years</td><td rowspan="1" colspan="1">Asthma</td><td rowspan="1" colspan="1">PO 40 mg/d for a fortnight</td><td rowspan="1" colspan="1">ESS 18, MSLT:<break/>s.l. 3 m, SOREMs 2</td><td rowspan="1" colspan="1">EDS improvement, and withdrawal of methylphenidate for 4 weeks after treatment</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1">[<xref rid="cit0068" ref-type="bibr">68</xref>]</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">29, F</td><td rowspan="1" colspan="1">9 years</td><td rowspan="1" colspan="1">Inflammatory transverse myelitis</td><td rowspan="1" colspan="1">IVMP (unknown dose)</td><td rowspan="1" colspan="1">At onset:<break/>ESS 20, MSLT:<break/>s.l. 1 m, SOREMs 3</td><td rowspan="1" colspan="1">Unchanged after treatment</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="3" colspan="1">[<xref rid="cit0074" ref-type="bibr">74</xref>]</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">60, F</td><td rowspan="1" colspan="1">2 months</td><td rowspan="1" colspan="1">Initial diagnosis of paraneoplastic syndrome</td><td rowspan="1" colspan="1">5-day course PLEX</td><td rowspan="1" colspan="1">ESS N/A, CPL 75–100/d</td><td rowspan="1" colspan="1">80% reduction of symptoms</td><td rowspan="1" colspan="1">Symptoms reappeared after 3 days;<break/>hcrt-1 70, MSLT:<break/>s.l. 1.8 m, SOREMs 2</td><td rowspan="1" colspan="1">Severe catheter infection</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">AZA</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Suspended</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Hepatitis</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IVIG</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">No effects</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">None</td></tr></tbody></table><table-wrap-foot><fn id="tfn0001"><p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="neither"> ↓, reduction; AZA, azathioprine; CPL, cataplexy; d, days; EDS, excessive daytime sleepiness; ESS, Epworth sleepiness scale; F, female; hcrt-1, hypocretin-1 CSF levels (expressed in pg/mL); IVIG intravenous immunoglobulin; IVMP, intravenous methylprednisolone; M, male; m, minutes; MSLT, multiple sleep latency test; N/A not available; PLEX, plasmapheresis; PO, prednisone; s.l., sleep latency; SOREMs, sleep onset REM periods; w, week(s).</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis></p>
        <p><citation_analysis attribute="positive">In other cases, corticosteroids were used as add-on therapy. However, overall results were negative. A 10-year-old child with a 3-month NT1 history was initially treated with IVIG infusion (1g/kg/day for 2 days) but later switched on prednisolone (1.3 mg kg/day) therapy for 3 weeks, due to side effects. Both EDS and cataplexy improved during steroid therapy but reappeared following treatment tapering. Despite the reported symptoms improvement, no changes of CSF hypocretin-1 levels were detected.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0070" ref-type="bibr">70</xref></citation_analysis><citation_analysis attribute="neither"> Similarly, two children, one with post-Pandemrix and one with sporadic NT1, respectively, received IVIG (1 g/kg/day for 2 days), followed by IVMP (20 mg/kg/day for 4 days) infusions repeated 3 times at monthly intervals.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0071" ref-type="bibr">71</xref></citation_analysis><citation_analysis attribute="neither"> In the first child, a marked improvement of EDS and cataplexy was observed, but symptoms gradually reemerged within 1–2 weeks from treatment, although two follow-up MSLTs showed normal sleep latencies. In the second child, only a transient amelioration of sleepiness and cataplexy was noted. In both cases, hypocretin levels remained low, and indeed dropped despite treatment in patient 1. However, the improvement of cataplexy that occurred during IVMP treatment suggests that steroids could exert an immunomodulating effect, explaining the improvement of cataplexy in these cases</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0071" ref-type="bibr">71</xref></citation_analysis><citation_analysis attribute="positive"> and in one of the previously reported cases.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0069" ref-type="bibr">69</xref></citation_analysis><citation_analysis attribute="positive"> Nevertheless, corticosteroids have several effects on the central nervous system,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0072" ref-type="bibr">72</xref></citation_analysis><citation_analysis attribute="neither"> therefore, although unlikely, a direct anticataleptic activity, ie, through their action on noradrenergic and serotoninergic neurotransmission, cannot be excluded.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0073" ref-type="bibr">73</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">PLEX is a very well-established treatment for antibody-mediated disorders. However, only a transitory benefit was observed in the single NT1 case treated so far with this procedure.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0074" ref-type="bibr">74</xref></citation_analysis><citation_analysis attribute="negative"> Indeed, despite an early treatment, within 2 months after onset, and an initial amelioration, the symptoms reemerged after few days. The patient was switched on IVIG therapy, but no further improvement was noticed (</citation_analysis><citation_analysis attribute="positive"><xref rid="t0001" ref-type="table">Table 1</xref></citation_analysis><citation_analysis attribute="positive">). The transient benefit observed with PLEX could be related to the removal of antibodies or other molecules (ie, cytokines) by this procedure, whilst its short duration as well as the lack of response to IVIG, suggest a placebo effect, or a different pathogenic mechanism, as discussed by the same authors. Indeed, the lack of a sustained effect of PLEX is in line with the lack of evidence supporting a central role of antibodies in the pathogenesis of narcolepsy (see above).</citation_analysis></p>
        <p><citation_analysis attribute="positive">IVIG have been more extensively employed in NT1, although mostly in single cases and small case series (without any randomized controlled trial approach to date) possibly because the first few observations seemed to provide positive results. A summary of the results of these studies is given in </citation_analysis><citation_analysis attribute="positive"><xref rid="t0002" ref-type="table">Table 2</xref></citation_analysis><citation_analysis attribute="neither"> and </citation_analysis><citation_analysis attribute="positive"><xref ref-type="fig" rid="f0001">Figure 1</xref></citation_analysis><citation_analysis attribute="neither">. Dauvilliers et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0075" ref-type="bibr">75</xref></citation_analysis><citation_analysis attribute="positive"> treated with IVIG four typical NT1 patients with low CSF hypocretin-1. The three cases treated close to onset showed a reduction of the frequency and severity of cataplexy, whereas an improvement of the mean sleep latency on the maintenance of wakefulness test (MWT) was observed in the patient with a 9-year disease history. These positive effects continued over time.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0076" ref-type="bibr">76</xref></citation_analysis><citation_analysis attribute="neither"> ESS scores improved during IVIG treatment in all cases. However, the concentration of hypocretin-1 in the CSF remained unchanged in two of the three available cases, whereas in one patient a slight increase was detected. This study pinpointed the importance of an early intervention, before the complete loss of hypocretinergic neurons, in ensuring a good outcome. This hypothesis seemed confirmed by a case where IVIG treatment, started 15 days after NT1 onset, led to cataplexy frequency reduction and CSF hypocretin-1 levels normalization. However, treatment discontinuation was followed by a progressive reoccurrence of NT1 symptoms after 4 months.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0077" ref-type="bibr">77</xref></citation_analysis><citation_analysis attribute="positive"> In three other cases treated within 1–4 months from symptoms’ onset mixed effects were observed, with some improvement of EDS, and in two cases also of cataplexy, although no significant changes of polysomnographic parameters were documented.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0078" ref-type="bibr">78</xref></citation_analysis><citation_analysis attribute="neither"> A 16-year-old girl with NT1 and severe bizarre hallucinations, with an inflammatory CSF (positive oligoclonal bands and pleocytosis) and undetectable hcrt-1 levels at the baseline examination, was treated with IVIG and showed only a transient improvement of the hallucinations. Interestingly, the CSF pleocytosis gradually disappeared after treatment, but CFS hcrt-1 levels remained unchanged.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0079" ref-type="bibr">79</xref></citation_analysis><citation_analysis attribute="positive"> Among 4 NT1 children with undetectable CSF hypocretin-1, treated with IVIG for 6 months within 1 year from onset, only one case showed a significant reduction of EDS and cataplexy frequency whereas in the others no persistent clinical changes were noted.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0080" ref-type="bibr">80</xref></citation_analysis><citation_analysis attribute="neither"> The short-lived benefit induced by therapy was confirmed by three further pediatric cases, treated close to onset</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0081" ref-type="bibr">81</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0082" ref-type="bibr">82</xref></citation_analysis><citation_analysis attribute="neither"> and in 4 idiopathic adult cases with various disease durations.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0083" ref-type="bibr">83</xref></citation_analysis><citation_analysis attribute="positive"> The often-transient nature of the benefit obtained by treatment suggested a possible placebo effect, as indeed demonstrated in a double-blind placebo-controlled single-case trial. A woman with a 7-year history of NT1 received alternatively IVIG or placebo and reported an improvement of her cataplexy whilst under either treatment.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0084" ref-type="bibr">84</xref></citation_analysis><citation_analysis attribute="positive"> A larger longitudinal non-randomized, retrospective study including a pediatric NT1 population, evaluated the effects of IVIG in 22 patients compared to 30 controls who received standard therapy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0085" ref-type="bibr">85</xref></citation_analysis><citation_analysis attribute="positive"> The study failed to show an effect of the IVIG treatment, although among patients with more severe symptoms, those receiving IVIG achieved remission earlier than controls. On the other hand, an improvement of symptoms in the treatment group was observed already before IVIG administration. Shorter disease duration did not correlate with response to treatment. The results of this study however cannot be considered as conclusive since the non-randomized study design could have introduced a selection bias. Indeed, baseline symptoms scores were higher in patients treated with IVIG compared to controls.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0085" ref-type="bibr">85</xref></citation_analysis><citation_analysis attribute="positive"> This selection bias, together with the significant spontaneous amelioration of cataplexy and EDS documented in non-treated NT1 children underline the probable significant bias in the observations obtained without any randomized study design.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0086" ref-type="bibr">86</xref></citation_analysis><citation_analysis attribute="positive"><table-wrap id="t0002" orientation="landscape" position="float"><label>Table 2</label><caption><p><citation_analysis attribute="neither">Summary of NT1 Cases Treated Mainly with IVIG</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Ref.</th><th rowspan="1" colspan="1">Study Design</th><th rowspan="1" colspan="1">Case</th><th rowspan="1" colspan="1">Age, Sex</th><th rowspan="1" colspan="1">Disease Duration</th><th rowspan="1" colspan="1">Scheme</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">After 1st Trial</th><th rowspan="1" colspan="1">After 2nd Trial</th><th rowspan="1" colspan="1">After 3rd Trial</th><th rowspan="1" colspan="1">After 4th Trial</th><th rowspan="1" colspan="1">Follow Up</th><th rowspan="1" colspan="1">≥ 2 y FU</th><th rowspan="1" colspan="1">Side Effects</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">[75, 76]</td><td rowspan="1" colspan="1">case series</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">10,M</td><td rowspan="1" colspan="1">4 months</td><td rowspan="1" colspan="1">IVIG 1g/kg/d over 2 days, for three times every 4 weeks</td><td rowspan="1" colspan="1">ESS 18,<break/>CPL&gt;1/d, hcrt-1 0, MSLT:<break/>s.l. 3 m,<break/>SOREMs 5</td><td rowspan="1" colspan="1">ESS 8.7±5.2,<break/>MSLT:<break/>s.l. 1.1 m, SOREMs 5</td><td rowspan="1" colspan="1">ESS 5.7±4.4<break/>MSLT:<break/>s.l. 0.8 m<break/>SOREMs 4</td><td rowspan="1" colspan="1">ESS<break/>1.2±4.4, CPL&lt;3/m<break/>hcrt-1 79 MSLT:<break/>s.l.. 1.2 m<break/>SOREMs 5</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Persistent effect on CPL at 8 months FU</td><td rowspan="1" colspan="1">ESS 12, CPL &lt;2/m</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">21,M</td><td rowspan="1" colspan="1">2 months</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ESS 13,<break/>CPL 2-3/d, hcrt-1 &lt;40, MSLT:<break/>s.l. 5 m, SOREMs 5</td><td rowspan="1" colspan="1">ESS 9.8 ± 1.9,<break/>MSLT:<break/>s.l. 2.9 m SOREMs5</td><td rowspan="1" colspan="1">ESS 8.7±1.1<break/>MSLT: s.l. 2.8 m<break/>SOREMs 5</td><td rowspan="1" colspan="1">ESS 8.7±1.6<break/>CPL&lt;5/m, hcrt-1 &lt;40 MSLT:<break/>s.l. 4.1 m, SOREMs 5</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Persistent effect on CPL at 8 months FU</td><td rowspan="1" colspan="1">ESS 8, CPL &lt; 4/m</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">12,F</td><td rowspan="1" colspan="1">8 months</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ESS 21,<break/>CPL&gt;2/d, hcrt-1 &lt;40 MWT:<break/>s.l. 1.4 m,<break/>SOREMs 4</td><td rowspan="1" colspan="1">ESS 14.3 ± 2.1,<break/>MWT<break/>s.l. 2.1 m, SOREMs 2</td><td rowspan="1" colspan="1">ESS 7.2±2.3<break/>MWT s.l. 3.6 m, SOREMs 4</td><td rowspan="1" colspan="1">ESS 7.1±2.CPL&lt;1/m/<break/>MWT:<break/>s.l. 4.2 m, SOREMs 3</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">ESS 6 CPL<break/>&lt; 1/m at 5 months FU</td><td rowspan="1" colspan="1">ESS 9, CPL 2-3/w after 6 months from IVIG</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">45,M</td><td rowspan="1" colspan="1">9 years</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ESS 23,<break/>CPL 1-2/m, hcrt-1 &lt;40 MWT:<break/>s.l. 6.1 m,<break/>SOREMs 1</td><td rowspan="1" colspan="1">ESS 18.07±4.3<break/>MWT:<break/>s.l. 5.4 m SOREMs 1</td><td rowspan="1" colspan="1">ESS 10.4±2.9<break/>MWT:<break/>s.l. 9.2 m, SOREMs 0</td><td rowspan="1" colspan="1">ESS 14.6±1.7<break/>CPL &lt;1-3/m, hcrt-1 &lt;40 MWT: s.l. 14.9 m, SOREMs 0</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">ESS 14 but no cataplexy at 4 months FU</td><td rowspan="1" colspan="1">ESS 6, cataplexy &lt; 1/m</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1">[84]</td><td rowspan="1" colspan="1">double-blind placebo-controlled<break/>n = 1 trial</td><td rowspan="1" colspan="1">5</td><td rowspan="1" colspan="1">55, F</td><td rowspan="1" colspan="1">7 years</td><td rowspan="1" colspan="1">IVIG 1g/kg/day over 2 days, repeated once after 6 m</td><td rowspan="1" colspan="1">ESS N/A; CPL 3-4/d</td><td rowspan="1" colspan="1">↓ CPL</td><td rowspan="1" colspan="1">↓ CPL</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">4 trials with IVIG or placebo</td><td rowspan="1" colspan="1">↓ CPL either after placebo or treatment</td><td rowspan="1" colspan="1">↓ CPL either after placebo or treatment</td><td rowspan="1" colspan="1">↓ CPL either after placebo or treatment</td><td rowspan="1" colspan="1">↓ CPL either after placebo or treatment</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1">[80]</td><td rowspan="1" colspan="1">case series</td><td rowspan="1" colspan="1">6</td><td rowspan="1" colspan="1">8, M</td><td rowspan="1" colspan="1">11 months</td><td rowspan="1" colspan="1">IVIG 0.4 g/kg/d for 5 days, monthly for 3 m followed by the same single day dose every month for the following 6 m</td><td rowspan="1" colspan="1">PDSS 23, CPL &gt;40/d, hcrt-1 0, MSLT:<break/>s.l. 2.24, SOREMs 2</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">PDSS 19, CPL&gt; 40/d MSLT:<break/>s.l. 2.36, SOREMs 5</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">7</td><td rowspan="1" colspan="1">8, F</td><td rowspan="1" colspan="1">12 months</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PDSS 32, CPL &gt;40/d, hcrt-1 0, MSLT:<break/>s.l. 1.36 m, SOREMs 5</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">PDSS 27, CPL &gt; 40, /<break/>MSLT:<break/>s.l. 36 s SOREMs 5</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">8</td><td rowspan="1" colspan="1">13, F</td><td rowspan="1" colspan="1">9 months</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PDSS 11, CPL 20-30/d<break/>hcrt-1 0, MSLT:<break/>s.l. 3.44 m, SOREMs 4</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">PDSS 6, CPL 4-5/d,<break/>MSLT: s.l. 3’50”, SOREMs4</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">9</td><td rowspan="1" colspan="1">6, M</td><td rowspan="1" colspan="1">4 months</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">PDSS 26, CPL &gt;40, hcrt-1 0, MSLT:<break/>s.l. 1.30 m, SOREMs 4</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">PDSS 12, CPL &gt;40, MSLT:<break/>s.l. 1.30m SOREMs 5</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Skin reaction (urticaria and petechiae), 5 d after T5, T6 and T7 IVIG infusion</td></tr><tr><td rowspan="1" colspan="1">[83]</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">10</td><td rowspan="1" colspan="1">43,F</td><td rowspan="1" colspan="1">3-4 months</td><td rowspan="1" colspan="1">IVMP 1000 mg/d for 3 days followed by 8 days of OP</td><td rowspan="1" colspan="1">ESS 19, CPL 2/d, hcrt-1 &lt;40 MSLT:<break/>s.l. &lt;2’, SOREMs 4, MWT:<break/>s.l. 7 m SOREMs 2</td><td rowspan="1" colspan="1">Self-reported mild but transient ↓ EDS and cataplexy</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">none</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IVIG 1g/kg/d over 2d repeated three times at 5-week intervals</td><td rowspan="1" colspan="1">ESS 15, CPL 1/d, MSLT:<break/>s.l. 2 m<break/>MWT:<break/>s.l. 5 m</td><td rowspan="1" colspan="1">ESS 11, CPL 1/d, MSLT:<break/>s.l. 5 m, MWT:<break/>s.l. &lt;2 m</td><td rowspan="1" colspan="1">ESS 17, CPL 1-2/d, MSLT: s.l. &lt;2 m<break/>MWT: s.l. &lt;2 m</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">ESS 17, CPL 1-2/d, MSLT: s.l. N/A, MWT: s.l. N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">11</td><td rowspan="1" colspan="1">59,F</td><td rowspan="1" colspan="1">16 years</td><td rowspan="1" colspan="1">IVIG 20 g every 3 w and one year later 2g/kg over 5 days</td><td rowspan="1" colspan="1">ESS 19, CPL 1-3/d, hcrt 1 0, MSLT:<break/>s.l. &lt;3’,<break/>2 SOREMs, MWT:<break/>s.l. 9 m</td><td rowspan="1" colspan="1">ESS 20, CPL 2/d, MSLT:<break/>s.l. &lt;3 m</td><td rowspan="1" colspan="1">ESS 20, CPL 2/d</td><td rowspan="1" colspan="1">ESS 20, CPL 2/d</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">ESS 20,<break/>CPL 2/d</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Allergy</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">12</td><td rowspan="1" colspan="1">41,M</td><td rowspan="1" colspan="1">4 years</td><td rowspan="1" colspan="1">IVIG 1g/kg/dover 2 days, repeated three times at 5-week intervals</td><td rowspan="1" colspan="1">ESS 22, CPL 3-4/d, hcrt-1 0, MSLT:<break/>s.l. &lt;1 m<break/>SOREMs 4,<break/>MWT:<break/>s.l. 5 m</td><td rowspan="1" colspan="1">ESS 11, CPL 1-2/w,<break/>MSLT:<break/>s.l. &lt;1 m MWT:<break/>s.l. 5 m</td><td rowspan="1" colspan="1">ESS 14, CPL 0-1/w,<break/>/<break/>MSLT: s.l.&lt;1m<break/>MWT: s.l. 10 m</td><td rowspan="1" colspan="1">ESS 14, CPL 0-1/w,<break/>/<break/>MSLT: s.l.&lt;1m<break/>MWT:<break/>s.l. 3 m</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">ESS 16, CPL<break/>3-4/d</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">13</td><td rowspan="1" colspan="1">52,F</td><td rowspan="1" colspan="1">11 months</td><td rowspan="1" colspan="1">IVIG 1g/kg/d over 2 days, repeated three times at 5-week intervals</td><td rowspan="1" colspan="1">ESS 17, CPL&gt;10/d, hcrt-1 0, MSLT: s.l. &lt;2 m SOREMs 2, MWT:<break/>s.l. 5 m</td><td rowspan="1" colspan="1">ESS 17, CPL 6/d,<break/>MSLT:<break/>s.l. &lt;2 m MWT:<break/>s.l. &lt;2 m</td><td rowspan="1" colspan="1">ESS 18,<break/>CPL 5/d MSLT: s.l.&lt;8m<break/>MWT s.l.&lt;1m</td><td rowspan="1" colspan="1">ESS 18, CPL 6/d,<break/>MSLT: sleep lat 1’, MWT sleep lat &lt;2’</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">ESS 18, CPL 5/d</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1">[77]</td><td rowspan="1" colspan="1">case report</td><td rowspan="1" colspan="1">14</td><td rowspan="1" colspan="1">28,F</td><td rowspan="1" colspan="1">15 days</td><td rowspan="1" colspan="1">IVIG 1g/kg/d over 2 days, repeated three times at 4-week intervals</td><td rowspan="1" colspan="1">ESS 21, CPL &gt;1/d, hcrt-1 0, MSLT:<break/>s.l. 5 m, SOREMs 2</td><td rowspan="1" colspan="1">↓ CPL</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">hcrt-1 339, MSLT:<break/>s.l. 8.6, SOREMs 0</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Reoccurrence of CPL and EDS after 4 months</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1">[81]</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">15</td><td rowspan="1" colspan="1">12,M</td><td rowspan="1" colspan="1">5 1/2 months</td><td rowspan="1" colspan="1">IVIG treatment of 1 g/kg/d for 2 days repeated 4 times at monthly inter- vals</td><td rowspan="1" colspan="1">ESS 9,<break/>CPL 2-4/d, hcrt-1 20, MSLT:<break/>s.l. 4.1 m, SOREMs 5</td><td rowspan="1" colspan="1">ESS 4,<break/>CPL 3/d</td><td rowspan="1" colspan="1">ESS 4, CPL 3/d</td><td rowspan="1" colspan="1">ESS 5, CPL 2-3/d</td><td rowspan="1" colspan="1">ESS 8, CPL 1-2/d</td><td rowspan="1" colspan="1">ESS 8, CPL 1-2/d, hcrt-1 &lt;10<break/>MSLT: s.l. 2.2 m, SOREMs 5</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">16</td><td rowspan="1" colspan="1">10,F</td><td rowspan="1" colspan="1">3 1/2 months</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ESS 21, CPL 2/d, hcrt-1 24, MSLT:<break/>s.l. 1 m, SOREMs 4</td><td rowspan="1" colspan="1">ESS 10-16, CPL few/w</td><td rowspan="1" colspan="1">ESS 4-12</td><td rowspan="1" colspan="1">ESS 4-12</td><td rowspan="1" colspan="1">ESS 4-12</td><td rowspan="1" colspan="1">ESS 4-12, CPL 2/d, hcrt-1 &lt;10 MSLT s.l. 2.3 m, SOREMs 3</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1">[89]</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">17</td><td rowspan="1" colspan="1">21, M</td><td rowspan="1" colspan="1">22 days</td><td rowspan="1" colspan="1">IVIG treatment of 1 g/kg/day for 2 days</td><td rowspan="1" colspan="1">ESS 18, CPL sub-continuous, hcrt-1 &lt;10, MSLT: s.l. 2.1 m, SOREMs 4</td><td rowspan="1" colspan="1">ESS 15-17, CPL very frequent, hcrt-1 &lt;10, MSLT:<break/>s.l. 36s<break/>SOREMs 5</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Headache and ↑ CSF leukocyte</td></tr><tr><td rowspan="1" colspan="1">[71]</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">18</td><td rowspan="1" colspan="1">2.5, M</td><td rowspan="1" colspan="1">1 month</td><td rowspan="1" colspan="1">IVIG 1g/kg/d for 2 days, followed by IVMP 20 mg/kg/ d for 4 for 3 times monthly</td><td rowspan="1" colspan="1">ESS 14, CPL several/d, hcrt-1 77 MSLT:<break/>s.l. 5 m, SOREMs 4/4</td><td rowspan="1" colspan="1">ESS 3, CPL 0 but reappeared 1-2 w after treatment</td><td rowspan="1" colspan="1">ESS 2, CPL 0 but reappeared 1-2 w after treatment</td><td rowspan="1" colspan="1">ESS 7, CPL 6/d, hcrt-1 &lt;40 MSLT:<break/>s.l. 11.5 m, SOREMs 3/4</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">ESS 12, CPL 1/d,<break/>MSLT: s.l. 12.5 m, SOREMs 5</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">19</td><td rowspan="1" colspan="1">6, M</td><td rowspan="1" colspan="1">4 months, 2 months from CPL</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ESS 17, CPL 8/d, hcrt 1 &lt;40, MSLT<break/>s.l. 2.1 m, SOREMs 4</td><td rowspan="1" colspan="1">ESS 11, CPL 6/d</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">ESS 16, CPL 6-7/d,<break/>Hcrt-1 &lt;40</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1">[82]</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">20</td><td rowspan="1" colspan="1">13, F</td><td rowspan="1" colspan="1">3 months</td><td rowspan="1" colspan="1">IVIG unknown dose</td><td rowspan="1" colspan="1">ESS 11, CPL &gt;10/d</td><td rowspan="1" colspan="1">ESS 11, CPL &gt;10 d</td><td rowspan="1" colspan="1">ESS 2, CPL &gt;10/d</td><td rowspan="1" colspan="1">ESS 2, CPL 10/d</td><td rowspan="1" colspan="1">ESS 4, CPL 3-4/d</td><td rowspan="1" colspan="1">ESS 4, CPL 2-3/d</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1">[78]</td><td rowspan="1" colspan="1">Case series</td><td rowspan="1" colspan="1">21</td><td rowspan="1" colspan="1">27, M</td><td rowspan="1" colspan="1">1 month after CPL</td><td rowspan="1" colspan="1">IVIG<break/>1g/kg/d for 2 days repeated 3 times at 4-week intervals</td><td rowspan="1" colspan="1">ESS N/A, naps ≤3/d, CPL &gt;5/d, hcrt-1 &lt;40, MSLT:<break/>s.l. 5.8 m, SOREMs 3</td><td rowspan="1" colspan="1">naps 1/d, CPL ≤2/d, MSLT:<break/>s.l. 1.6 m, SOREMs 3</td><td rowspan="1" colspan="1">naps 1/d, CPL 2/w, MSLT: s.l. 2.1 m, SOREMs 3</td><td rowspan="1" colspan="1">naps 1/d, CPL 2/w, MSLT:<break/>s.l. 2 m, SOREMs 4</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">naps 1-2/d, CPL &gt;5/w</td><td rowspan="1" colspan="1">N/A</td><td rowspan="3" colspan="1">Some transient complaints of minor headache. The two children had infectious episodes, a ﬂu-like syndrome for one and viral gastroenteritis for the other, leading to a few missed school days.</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">22</td><td rowspan="1" colspan="1">10, F</td><td rowspan="1" colspan="1">2 months after CPL</td><td rowspan="1" colspan="1">IVIG treatment of 1 g/kg/day for 1 day repeated 3 times at 4-week intervals</td><td rowspan="1" colspan="1">ESS N/A, naps 5-6/d, CPL &gt;5/d, hcrt-1 &lt;40, MSLT<break/>s.l. 3.8 m, SOREMs 4</td><td rowspan="1" colspan="1">naps 5-6/d, CPL ≤3/d, MSLT:<break/>s.l. 3.2 m, SOREMs 5</td><td rowspan="1" colspan="1">naps 5-6/d, CPL &gt;5/d, MSLT: s.l. 1.2 m, SOREMs 5</td><td rowspan="1" colspan="1">naps 5-6/d, CPL &gt;5/d, MSLT<break/>s.l. 0.7 m, SOREMs 4</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">naps 0, CPL 3/w</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">23</td><td rowspan="1" colspan="1">7, M</td><td rowspan="1" colspan="1">4 months after CPL</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ESS N/A, naps 2/d, CPL &lt;1/d, hcrt-1 &lt;40 MSLT<break/>s.l. 8 m, SOREMs 2</td><td rowspan="1" colspan="1">naps ≤2/d, CPL &lt;1/w, MSLT:<break/>s.l. 2.9 m, SOREMs 3</td><td rowspan="1" colspan="1">naps ≤2/d, CPL &lt;1/w, MSLT: s.l. 2.6 m, SOREMs 5</td><td rowspan="1" colspan="1">naps ≤2/d, cataplexy &lt;1/w, MSLT:<break/>s.l. 9.2 m, SOREMs 5</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">naps 1/d, CPL 0</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1">[79]</td><td rowspan="1" colspan="1">Case report</td><td rowspan="1" colspan="1">24</td><td rowspan="1" colspan="1">16,F</td><td rowspan="1" colspan="1">/</td><td rowspan="1" colspan="1">IVIG 0.4 g/<break/>kg/d over 5 days repeated three times every 6 weeks</td><td rowspan="1" colspan="1">ESS 23,<break/>hcrt-1 0 MSLT: s.l. 1 m, SOREMs 4</td><td rowspan="1" colspan="1">↓hallucinations,<break/>EDS and cataplexy unchanged hcrt-1 0</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Bizarre and disruptive hallucinations<break/>and severe dream-reality confusion; EDS and CPL unchanged</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"><bold>Ref.</bold></td><td rowspan="1" colspan="1"><bold>Study design</bold></td><td rowspan="1" colspan="1"><bold>Participants</bold></td><td rowspan="1" colspan="1"><bold>Age, gender</bold></td><td rowspan="1" colspan="1"><bold>Disease duration</bold></td><td rowspan="1" colspan="1"><bold>Scheme</bold></td><td rowspan="1" colspan="1"><bold>Baseline</bold></td><td rowspan="1" colspan="1"><bold>0-6 months after IVIG</bold></td><td rowspan="1" colspan="1"><bold>6-12 months after IVIG</bold></td><td rowspan="1" colspan="1"><bold>12-18 months after IVIG</bold></td><td rowspan="1" colspan="1"><bold>18-24 months after IVIG</bold></td><td rowspan="1" colspan="1"><bold>&gt;24 months after IVIG</bold></td><td rowspan="1" colspan="1"><bold>Comments</bold></td><td rowspan="1" colspan="1"><bold>Side effects</bold></td></tr><tr><td rowspan="1" colspan="1">[85]</td><td rowspan="1" colspan="1">Non-randomized, open-label, retrospective</td><td rowspan="1" colspan="1">22 patients receiving IVIG</td><td rowspan="1" colspan="1">9.7 ± 2.6 y, 12 M</td><td rowspan="1" colspan="1">0.7 (0.01-2.4)*</td><td rowspan="1" colspan="1">IVIG 1g/kg/d 1 infusion for 3 times every month</td><td rowspan="1" colspan="1">PDSS 17.7 ± 6.2,<break/>CASS 16.3 ± 4.7,<break/>UNS 25.8 ± 6-8,<break/>CG1-cataplexy 3 (0-6),<break/>CGI-sleepiness 4 (2-5) MSLT<break/>s.l. 4.1 (2-11)*</td><td rowspan="1" colspan="1">No significant change in any parameter</td><td rowspan="1" colspan="1">No significant change in any parameter</td><td rowspan="1" colspan="1">No significant change in any parameter</td><td rowspan="1" colspan="1">No significant change in any parameter</td><td rowspan="1" colspan="1">No significant change in any parameter</td><td rowspan="2" colspan="1">In patients with high baseline symptoms, a subset of IVIg- treated patients achieved remission more rapidly than control patients.</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">30 patients receiving standard treatment</td><td rowspan="1" colspan="1">9.5 ± 3.3 y, 17 M</td><td rowspan="1" colspan="1">1.4 (0.1-6.5)</td><td rowspan="1" colspan="1">standard treatment</td><td rowspan="1" colspan="1">PDSS 18.5 ± 6,<break/>CASS 14.8 ± 6.1,<break/>UNS 22.6 ± 8.4,<break/>CGI-cataplexy 3 (0-6),<break/>CGI-sleepiness 4 (2-6) MSLT<break/>s.l. 6.9 (2-26)</td><td rowspan="1" colspan="1">No significant change in any parameter</td><td rowspan="1" colspan="1">No significant change in any parameter</td><td rowspan="1" colspan="1">No significant change in any parameter</td><td rowspan="1" colspan="1">No significant change in any parameter</td><td rowspan="1" colspan="1">No significant change in any parameter</td><td rowspan="1" colspan="1">None</td></tr></tbody></table><table-wrap-foot><fn id="tfn0002"><p><citation_analysis attribute="positive"><bold>Note:</bold></citation_analysis><citation_analysis attribute="neither"> *Value significantly different from controls.</citation_analysis></p></fn><fn id="tfn0003"><p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="neither"> ↑, increase; ↓, reduction; CASS, Child and Adolescent Sleepiness Scale; CGI, clinical global impression scale; CPL, cataplexy; CSF, cerebrospinal fluid; d, days; EDS, excessive daytime sleepiness; ESS, Epworth sleepiness scale; F, female; hcrt-1, hypocretin-1 CSF levels (expressed in pg/mL); IVIG, intravenous immunoglobulin; IVMP, intravenous methylprednisolone; M, male; m, minutes; MSLT, multiple sleep latency test; MWT, maintenance of wakefulness test; N/A, not available; PDSS, pediatric daytime sleepiness scale; PLEX, plasmapheresis; PO, prednisone; s, seconds; s.l., sleep latency; SOREMs, sleep onset REM periods; UNS, Ullanlinna narcolepsy scale; w, week(s).</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><fig id="f0001" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p><citation_analysis attribute="positive">Outcomes of IVIG treatment in children and adults NT1 patients. The graphs show the individual patients outcome assessment values at baseline and after each IVIG infusion. Each line represents a single individual, numbered according to the case numbers in </citation_analysis><citation_analysis attribute="positive"><xref rid="t0002" ref-type="table">Table 2</xref></citation_analysis><citation_analysis attribute="positive">. No significant variations were observed in the majority of cases in respects to cataplexy frequency (</citation_analysis><citation_analysis attribute="positive"><bold>A</bold></citation_analysis><citation_analysis attribute="neither">), sleep latency at the multiple sleep latency test (MSLT) (</citation_analysis><citation_analysis attribute="positive"><bold>B</bold></citation_analysis><citation_analysis attribute="neither">) or Epworth sleepiness scale (ESS) scores (</citation_analysis><citation_analysis attribute="positive"><bold>C</bold></citation_analysis><citation_analysis attribute="neither">) in children and adults.</citation_analysis></p></caption><graphic content-type="print-only" xlink:href="NSS-13-557-g0001"/></fig></citation_analysis></p>
        <p><citation_analysis attribute="neither">Indeed, notwithstanding prospective randomized studies, the utility of IVIG in the treatment of idiopathic NT1 remains to date unclear. In most cases, results have been disappointing or short-lasting. The benefits noted in some anecdotal reports could be related to both placebo effect and a spontaneous improvement of symptoms over time, as observed occasionally.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0085" ref-type="bibr">85–88</xref></citation_analysis><citation_analysis attribute="negative"> On the other hand, it cannot be excluded that in rare instances immunotherapy could partially reverse a hypofunction of hypocretin cells preceding their actual destruction, explaining the disappearance of cataplexy in few individual cases.</citation_analysis></p>
        <p><citation_analysis attribute="neither">Limited efficacy of IVIG therapy was also observed in post-vaccine narcolepsy, even when treatment was administered close to onset.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0089" ref-type="bibr">89</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0090" ref-type="bibr">90</xref></citation_analysis></p>
      </sec>
      <sec id="s0003-s2002">
        <title>Immunotherapies Targeting B and T Cells</title>
        <p><citation_analysis attribute="neither">A summary of the results of the studies employing these therapies is given in </citation_analysis><citation_analysis attribute="positive"><xref rid="t0003" ref-type="table">Tables 3</xref></citation_analysis><citation_analysis attribute="neither"> and </citation_analysis><citation_analysis attribute="positive"><xref rid="t0004" ref-type="table">4</xref></citation_analysis><citation_analysis attribute="neither">.</citation_analysis><citation_analysis attribute="positive"><table-wrap id="t0003" orientation="landscape" position="float"><label>Table 3</label><caption><p><citation_analysis attribute="neither">Summary of NT1 Cases Treated with Rituximab</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Ref.</th><th rowspan="1" colspan="1">Case</th><th rowspan="1" colspan="1">Age, Sex</th><th rowspan="1" colspan="1">Disease Duration</th><th rowspan="1" colspan="1">Additional Features</th><th rowspan="1" colspan="1">Scheme</th><th rowspan="1" colspan="1">Baseline</th><th rowspan="1" colspan="1">After 1st Trial</th><th rowspan="1" colspan="1">After 2nd Trial</th><th rowspan="1" colspan="1">After 3rd Trial</th><th rowspan="1" colspan="1">After 4th Trial</th><th rowspan="1" colspan="1">After 5th Trial</th><th rowspan="1" colspan="1">Side Effects</th></tr></thead><tbody><tr><td rowspan="2" colspan="1">[<xref rid="cit0090" ref-type="bibr">90</xref>]</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">12, M</td><td rowspan="1" colspan="1">45 days</td><td rowspan="1" colspan="1">Previous Pandemrix vaccination; 1 year after NC onset severe psychiatric symptoms</td><td rowspan="1" colspan="1">IVIG 1g/kg for 2 days</td><td rowspan="1" colspan="1">ESS N/A, CPL &gt;10/d, hcrt-1 0</td><td rowspan="1" colspan="1">No changes</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">Hypotension, nausea</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Rtx 500 mg x2, 500 mg after 6 months and 1000 mg x 5 at 1 week interval 1 year later</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">↓ ESS and CPL, beahvioural improvment lasting for 2 months</td><td rowspan="1" colspan="1">No changes</td><td rowspan="1" colspan="1">No changes; persistent psychiatric and behavioural disorders</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1">[<xref rid="cit0091" ref-type="bibr">91</xref>]</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">28, M</td><td rowspan="1" colspan="1">5 months EDS 2 monthsCPL</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Rtx1000 mg every 6 months (5 courses)</td><td rowspan="1" colspan="1">ESS 21 CPL 1–3/day Hctr-1 105 MSLT: s.l. 2.5 m;<break/>SOREMs 0</td><td rowspan="1" colspan="1">ESS 16–17, Hcrt-1 100-106, CPL 1–3/d</td><td rowspan="1" colspan="1">ESS 16–17, Hcrt-1 77–79, CPL 1–3/d</td><td rowspan="1" colspan="1">ESS 16–17, Hcrt-1 65–70, CPL 1–3/d</td><td rowspan="1" colspan="1">ESS 16–17, Hcrt-1 68, CPL 1–3/d</td><td rowspan="1" colspan="1">ESS 16–17, Hcrt-1 72–60, CPL 1–3/d</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="3" colspan="1">[<xref rid="cit0092" ref-type="bibr">92</xref>]</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">5, M</td><td rowspan="1" colspan="1">1 month</td><td rowspan="1" colspan="1">Brain MRI: Abnormal high signals in the right cerebellum and brachium pontis in FLAIR; negative and than positive AQ4-ab (interpreted as false positive)</td><td rowspan="1" colspan="1">IVIG 2g/kg for 4 days</td><td rowspan="1" colspan="1">EDS &gt; 3h CPL&gt;10/d MSLT s.l. 6.4 m SOREMs 4</td><td rowspan="1" colspan="1">EDS and CPL no change</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">IVMP 0.5 g/day x3 days (3 weeks) followed by oral PO</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">EDS 1 h/d<break/>CPL&lt;3/day</td><td rowspan="1" colspan="1">EDS 1 h/d<break/>CPL &lt;10/day</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Rtx 400 mg/4 weeks repeated after 6 months (2 courses)</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">EDS 1 h/day CPL &gt;10/day</td><td rowspan="1" colspan="1">EDS 1 h/day CPL &lt;10/day</td><td rowspan="1" colspan="1">EDS 1 h/day CPL<break/>&lt;10/d MSLT s.l. 2 m SOREMs 5</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">None</td></tr></tbody></table><table-wrap-foot><fn id="tfn0004"><p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="neither"> ↓, reduction; CPL, cataplexy; d, days; AQ4-ab, aquaporin-4 antibodies; EDS, excessive daytime sleepiness; ESS, Epworth sleepiness scale; F, female; hcrt-1, hypocretin-1 CSF levels (expressed in pg/mL); IVIG, intravenous immunoglobulin; IVMP, intravenous methylprednisolone; M, male; m, minutes; MSLT, multiple sleep latency test; N/A, not available; NC, narcolepsy; PO, prednisone; Rtx, rituximab; s.l., sleep latency; SOREMs, sleep onset REM periods.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis><citation_analysis attribute="positive"><table-wrap id="t0004" orientation="portrait" position="float"><label>Table 4</label><caption><p><citation_analysis attribute="neither">Summary of NT1 Cases Treated with T Cells Targeting Drugs</citation_analysis></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="1" colspan="1">Ref.</th><th rowspan="1" colspan="1">Case</th><th rowspan="1" colspan="1">Age, Sex</th><th rowspan="1" colspan="1">Disease Duration</th><th rowspan="1" colspan="1">Additional Features</th><th rowspan="1" colspan="1">Baseline Narcolepsy Feature</th><th rowspan="1" colspan="1">Treatment</th><th rowspan="1" colspan="1">Outcome</th><th rowspan="1" colspan="1">Follow-Up</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">[<xref rid="cit0093" ref-type="bibr">93</xref>]</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">79, M</td><td rowspan="1" colspan="1">62 years</td><td rowspan="1" colspan="1">Low-grade T-cell lymphoma</td><td rowspan="1" colspan="1">Daily CPL</td><td rowspan="1" colspan="1">Alemtuzumab</td><td rowspan="1" colspan="1">Disappearance of CPL the 1.5 y treatment</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="5" colspan="1">[<xref rid="cit0097" ref-type="bibr">97</xref>]</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">39, F</td><td rowspan="1" colspan="1">4 years (CPL)</td><td rowspan="1" colspan="1">RR MS since age 29 y</td><td rowspan="1" colspan="1">ESS 16, CPL +, hcrt-1 22, MSLT<break/>s.l. 4.5 m, SOREMs 3</td><td rowspan="1" colspan="1">IVIG</td><td rowspan="1" colspan="1">Short-term EDS improvement</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Interferon beta 1b, dimethyl fumarate</td><td rowspan="1" colspan="1">No effects</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1">2</td><td rowspan="1" colspan="1">45, F</td><td rowspan="1" colspan="1">28 years (EDS)</td><td rowspan="1" colspan="1">RR MS since age 40 y</td><td rowspan="1" colspan="1">ESS 17, CPL +, hcrt-1 &lt;20, MSLT:<break/>s.l. 1 m, SOREMs 3/4</td><td rowspan="1" colspan="1">Natalizumab</td><td rowspan="1" colspan="1">EDS improvement</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">26, F</td><td rowspan="1" colspan="1">12 years (EDS)</td><td rowspan="1" colspan="1">RR MS since age 19 y</td><td rowspan="1" colspan="1">ESS 14, CPL +, hcrt-1 N/A, MSLT<break/>s.l. 1 m, SOREMs 5</td><td rowspan="1" colspan="1">Interferon beta 1a</td><td rowspan="1" colspan="1">No effects</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1">4</td><td rowspan="1" colspan="1">45, F</td><td rowspan="1" colspan="1">9 years</td><td rowspan="1" colspan="1">RR MS since age 35 y</td><td rowspan="1" colspan="1">ESS 12, CPL +, hcrt-1 &lt;20, MSLT<break/>s.l. 1 m, SOREMs 2</td><td rowspan="1" colspan="1">Glatiramer acetate</td><td rowspan="1" colspan="1">No effects</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1">[<xref rid="cit0098" ref-type="bibr">98</xref>]</td><td rowspan="1" colspan="1">1</td><td rowspan="1" colspan="1">21, M</td><td rowspan="1" colspan="1">3 months</td><td rowspan="1" colspan="1">MS and narcolepsy after Pandemrix vaccination</td><td rowspan="1" colspan="1">N/A</td><td rowspan="1" colspan="1">IVMP 1 g/d for 3 days than natalizumab</td><td rowspan="1" colspan="1">No effects</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="2" colspan="1">[<xref rid="cit0101" ref-type="bibr">101</xref>]</td><td rowspan="1" colspan="1">3</td><td rowspan="1" colspan="1">21, F</td><td rowspan="1" colspan="1">1 month</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">ESS 18 CPL 5–10/d hctr-1 60 MSLT:<break/>s.l. 0.2 m; SOREMs 2</td><td rowspan="1" colspan="1">IVIG 2g/kg for 2 days</td><td rowspan="1" colspan="1">No effects</td><td rowspan="1" colspan="1">N/A</td></tr><tr><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">3 months</td><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1"/><td rowspan="1" colspan="1">Natalizumab 300 mg IV monthly; 12 doses total</td><td rowspan="1" colspan="1">hcrt-1 13.6</td><td rowspan="1" colspan="1">hcrt-1 17.8</td></tr></tbody></table><table-wrap-foot><fn id="tfn0005"><p><citation_analysis attribute="positive"><bold>Abbreviations:</bold></citation_analysis><citation_analysis attribute="neither"> +, present; CPL, cataplexy; d, days; EDS, excessive daytime sleepiness; ESS, Epworth sleepiness scale; F, female; hcrt-1, hypocretin-1 CSF levels (expressed in pg/mL); IVIG intravenous immunoglobulin; IV, intravenous; IVMP, intravenous methylprednisolone; M, male; m, minutes; MS, multiple sclerosis; MSLT, multiple sleep latency test; N/A not available; RR, relapsing remitting; s.l., sleep latency; SOREMs, sleep onset REM periods.</citation_analysis></p></fn></table-wrap-foot></table-wrap></citation_analysis><citation_analysis attribute="positive">
</citation_analysis></p>
        <p><citation_analysis attribute="neither">Rituximab is a monoclonal antibody targeting the CD20 antigen, mainly expressed on the surface of B cells. Upon binding to its target, this antibody mediates cells lysis with consequent B cells depletion. This therapy has proven effective in several antibody-mediated neurological disorders, including myasthenia gravis and autoimmune encephalitis. Recently, a 13-year-old boy, with post-Pandemrix NT1, treated with IVIG without benefit, received two rituximab infusions after the onset of a severe psychiatric disorder characterized by daytime hallucinations, behavioral problems and severe aggressivity requiring commitment to a psychiatric department.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0090" ref-type="bibr">90</xref></citation_analysis><citation_analysis attribute="positive"> After treatment, an improvement of narcolepsy symptoms and behavioural and psychiatric disorders was observed. However, this beneficial effect lasted only for 2 months and subsequent infusions did not have any effect. Another patient, a 28-year-old man was treated with 5 courses of rituximab (1000 mg every 6 months) 5 months after the onset of NT1. Despite a subjective improvement of EDS 1 month after each infusion, no change of cataplexy frequency was observed. Moreover, longitudinal assessment of hcrt-1 CSF levels showed a progressive decrement from 100 to around 60 pg/mL.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0091" ref-type="bibr">91</xref></citation_analysis><citation_analysis attribute="neither"> More recently, a 5-year-old boy, with NT1 and a suspected neuromyelitis optica spectrum disorder (NMOSD) was treated with a combination of IVIG, steroids and rituximab. A transitory improvement was noticed only after high dose IVMP treatment.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0092" ref-type="bibr">92</xref></citation_analysis><citation_analysis attribute="negative"> The failure of B cells depletion in reverting the disease course supports the lack of a major role of humoral immunity in driving the pathological process and suggests that treatments targeting the T- cells could be more effective.</citation_analysis></p>
        <p><citation_analysis attribute="neither">A 79-year-old man with a very long NT1 history was treated for a T-cell lymphoma with alemtuzumab,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0093" ref-type="bibr">93</xref></citation_analysis><citation_analysis attribute="neither"> a humanized monoclonal antibody directed against the CD52 antigen causing CD4+ T-cells suppression.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0094" ref-type="bibr">94</xref></citation_analysis><citation_analysis attribute="positive"> During treatment, the patient reported disappearance of cataplexy, but not of other disease manifestations. Interestingly, methotrexate, another immunosuppressive treatment acting on several immune cells, including T-cells,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0095" ref-type="bibr">95</xref></citation_analysis><citation_analysis attribute="positive"> which was administered before alemtuzumab, did not impact narcolepsy symptoms. Why and how alemtuzumab could selectively affect cataplexy, particularly in a patient with a 58-year history of cataplexy, is unclear. It is possible that this drug exerts other effects beside T-cells suppression, such as neuroprotection and repair.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0096" ref-type="bibr">96</xref></citation_analysis></p>
        <p><citation_analysis attribute="neither">Rarely, narcolepsy can develop together with multiple sclerosis (MS), either secondarily to hypothalamic demyelinating lesions or as a concomitant disorder.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0097" ref-type="bibr">97</xref></citation_analysis><citation_analysis attribute="positive"> In a small series of NT1 cases with concomitant MS, two patients reported EDS improvement upon treatment with IVIG and long-term steroid therapy, respectively.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0097" ref-type="bibr">97</xref></citation_analysis><citation_analysis attribute="positive"> Among the five patients receiving disease-modifying MS drugs, no response was observed with glatiramer acetate (n=1) or beta-interferon (n=2) and, of the two patients treated with natalizumab, only one reported reduction of EDS.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0097" ref-type="bibr">97</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0098" ref-type="bibr">98</xref></citation_analysis><citation_analysis attribute="positive"> It is unclear if this improvement is related to a direct effect of natalizumab on the pathogenic mechanism underlying narcolepsy or to a more complex effect, since natalizumab treatment was shown also to improve fatigue and EDS in MS patients without narcolepsy.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0099" ref-type="bibr">99</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0100" ref-type="bibr">100</xref></citation_analysis><citation_analysis attribute="neither"> Natalizumab is a recombinant monoclonal antibody directed against the cell adhesion molecule alpha4-integrin expressed on the surface of human leukocytes. This treatment is expected to prevent cellular infiltration of the CNS and could be a promising treatment for NT1. Recently, a 21-year-old woman was treated with IVIG followed by natalizumab 3 months after NT1 onset. Despite treatment, no symptoms improvement was noted and, on the contrary, CSF hypocretin-1 levels dropped from 70 pg/mL to 17 pg/mL.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0101" ref-type="bibr">101</xref></citation_analysis><citation_analysis attribute="positive"> Although disappointing, this result could be explained by the relatively delayed treatment, administered when most of the hypocretin secreting cells had already been lost.</citation_analysis></p>
        <p><citation_analysis attribute="neither">Cyclophosphamide (CYC) is an alkylating agent with antineoplastic and immunosuppressive and immunomodulating effects. Its cytotoxic activity is mainly due to DNA cross-linkage leading to cell apoptosis.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0102" ref-type="bibr">102</xref></citation_analysis><citation_analysis attribute="positive"> CYC induces B and T cells depletion therefore inhibiting both, humoral and cell-mediated immune response. However, it can also exert beneficial immunomodulatory effect by reducing the number of regulatory T-cells and inducing T-cells grow factors.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0103" ref-type="bibr">103</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0104" ref-type="bibr">104</xref></citation_analysis><citation_analysis attribute="neither"> CYC is highly effective in the treatment of several autoimmune conditions although is burden by several toxicities.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0105" ref-type="bibr">105</xref></citation_analysis><citation_analysis attribute="positive"> To our knowledge, to date, no patients with NT1 treated with CYC have been reported. However, disappearance of hypersomnia was reported in a 36-year-old woman who developed NT2 in the context of a neurolupus and was treated with 4 monthly CYC and IVIM infusions.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0106" ref-type="bibr">106</xref></citation_analysis><citation_analysis attribute="neither"> On the other hand, no benefit was observed in four patients with paraneoplastic NT1.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0107" ref-type="bibr">107–110</xref></citation_analysis></p>
        <sec id="s0003-s2002-s3001">
          <title>Side Effects of Immunotherapy</title>
          <p><citation_analysis attribute="positive">Corticosteroids and PLEX have been largely used in clinical practice to treat autoimmune disorders and adverse events are well known. In the few NT1 patients who underwent these treatments, side effects included acne and dermatitis</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0070" ref-type="bibr">70</xref></citation_analysis><citation_analysis attribute="neither"> and a severe catheter infection.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0074" ref-type="bibr">74</xref></citation_analysis><citation_analysis attribute="neither"> Although IVIG treatment is considered safe, side effects, even severe, can occur and were indeed observed also in NT1 patients. In adult cases, headache, sometimes associated with stiff neck</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0101" ref-type="bibr">101</xref></citation_analysis><citation_analysis attribute="neither"> or rise in CSF leukocytes,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0089" ref-type="bibr">89</xref></citation_analysis><citation_analysis attribute="neither"> was the most common complaint, whereas one patient presented a not better-defined allergic reaction.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0083" ref-type="bibr">83</xref></citation_analysis><citation_analysis attribute="positive"> In children, side effects included infectious episodes (a flu-like syndrome and viral gastroenteritis),</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0078" ref-type="bibr">78</xref></citation_analysis><citation_analysis attribute="neither"> skin reactions with urticaria and petechiae,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0080" ref-type="bibr">80</xref></citation_analysis><citation_analysis attribute="neither"> hypotension and nausea,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0090" ref-type="bibr">90</xref></citation_analysis><citation_analysis attribute="neither"> headache, fever, and flushing</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0070" ref-type="bibr">70</xref></citation_analysis><citation_analysis attribute="neither"> requiring therapy withdrawal.</citation_analysis></p>
          <p><citation_analysis attribute="neither">Although until now no serious adverse events occurred in NT1 patients treated with monoclonal antibodies, these drugs have potentially lethal side effects, ie, severe infusion-related reactions, secondary autoimmunity</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0094" ref-type="bibr">94</xref></citation_analysis><citation_analysis attribute="positive"> and life-threatening infections secondary to immunosuppression, in particular progressive multifocal leukoencephalopathy (PML). The risk of PML is higher in patients treated with drugs reducing T-cells trafficking to the brain such as natalizumab, but rare cases have been also reported in association with rituximab.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0111" ref-type="bibr">111</xref></citation_analysis><citation_analysis attribute="negative"> Therefore, clinicians should keep in mind this risk and predispose adequate monitoring. Scammel and colleagues</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0101" ref-type="bibr">101</xref></citation_analysis><citation_analysis attribute="negative"> proposed a treatment trial with natalizumab of a maximum of 1 or 2 years, to reduce the risk of PML in NT1 patients.</citation_analysis></p>
        </sec>
        <sec id="s0003-s2002-s3002">
          <title>Open Issues and Future Directions</title>
          <p><citation_analysis attribute="positive">Most of the information on the effects of immunotherapy in narcolepsy derive from uncontrolled case studies, with small sample sizes, different treatment schemes and highly heterogeneous outcome measures. Therefore, current data is not sufficient to support the use of immunotherapy for narcolepsy and randomized controlled clinical trials are needed to provide substantial evidence and avoid bias related to placebo effect and to spontaneous disease improvements. To date, most of the attempts to reverse NT1 symptoms have been disappointing, and this could be related to several open issues that need to be addressed and that are summarized below.</citation_analysis></p>
          <sec id="s0003-s2002-s3002-s4001">
            <title>What is the Best Immunomodulating/Immunosuppressive Treatment for Narcolepsy?</title>
            <p><citation_analysis attribute="positive">Since the autoimmune basis of narcolepsy remains unproven, and our understanding of the immune process involved is still limited (ie, associated or pathogenetic), it is difficult to provide a definite answer to this question. However, mounting evidence underpins the primary role of T-cells in NT1 disease pathogenesis. Many of the studies on immunotherapy have been focused on treatments acting mainly on the antibody-mediated immune response, possibly explaining the lack of a meaningful effect. T-cells targeting drugs have been only rarely employed; therefore, agents such as natalizumab or alemtuzumab could be promising treatments for future clinical trials.</citation_analysis></p>
          </sec>
          <sec id="s0003-s2002-s3002-s4002">
            <title>When to Treat?</title>
            <p><citation_analysis attribute="neither">This is an apparently easy question with a seemingly easy answer, the sooner, the better. Indeed, since immunotherapy might prevent the loss of the hypocretinergic neurons, it should be given before this process reach completion. On this assumption, many of the previous studies focused on treating patients close to disease onset. However, cataplexy manifests when most, about 80%, of the hypocretin-secreting neurons are already lost,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0112" ref-type="bibr">112</xref></citation_analysis><citation_analysis attribute="neither"> therefore it could be possibly more effective to treat patients who have not yet developed cataplexy. Although the natural history of the hypocretin cells death is unclear, most NT1 patients refer experiencing EDS months or years before the appearance of cataplexy</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0013" ref-type="bibr">13</xref></citation_analysis><citation_analysis attribute="positive"> implying a progression over time, as documented in few cases by hcrt-1 CSF assessment.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0007" ref-type="bibr">7–10</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41</xref></citation_analysis><citation_analysis attribute="positive"> These cases show that at least in few cases, narcolepsy symptoms evolve over time along with changes of CSF markers suggesting that in HLA DQB1*06:02 positive subjects with EDS and other narcolepsy features CSF markers should be monitored over time. This could potentially offer a window of opportunity to intervene with immunotherapies in early stages in order to try preventing or reducing the hypocretinergic neuronal loss. Interestingly, Latorre et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0041" ref-type="bibr">41</xref></citation_analysis><citation_analysis attribute="neither"> observed the presence of reactive CD8+ T-cell clones in the CSF of a recently diagnosed NT2 patient who later evolved into NT1 suggesting that these cells could be a potentially reliable early marker. The identification of early markers of progression could be crucial to identify those patients who could benefit from immunotherapy before the complete destruction of hypocretinergic neurons leading to NT1. On the other hand, CSF hypocretin loss can progress quickly and shortly after symptom onset,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0113" ref-type="bibr">113</xref></citation_analysis><citation_analysis attribute="neither"> even before the appearance of sleep-onset rapid eye movement periods, therefore prompt diagnosis and CSF examination are crucial for the identification of cases who can benefit from immunotherapy.</citation_analysis></p>
          </sec>
          <sec id="s0003-s2002-s3002-s4003">
            <title>How to Assess the Clinical Outcome?</title>
            <p><citation_analysis attribute="positive">Many of the cases reported so far used heterogeneous measurements, including subjective sleepiness scales, CSF hypocretin-1 levels, multiple sleep latency test (MSLT), MWT, alone or in various combinations, or patients’ self-reports to monitor the response to therapy. In certain cases, patients subjectively experienced an improvement of EDS or cataplexy, but the use of objective sleep parameters, often failed to pair these subjective evaluations, showing the intrinsic limitations of current methodology for the assessment of treatment efficacy, as well as their poor correlation with clinically relevant outcome measures.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0021" ref-type="bibr">21</xref></citation_analysis><citation_analysis attribute="neither"> For some narcolepsy manifestations including cataplexy or sleep paralysis, there are not appropriate assessment tools and only recently an overall narcolepsy severity scale has been proposed.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0114" ref-type="bibr">114</xref></citation_analysis><citation_analysis attribute="negative"> Most of the previous studies on IVIG efficacy involved children and employed the same tools used to evaluate adults, with only few studies adopting age-appropriate scales.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0080" ref-type="bibr">80</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0085" ref-type="bibr">85</xref></citation_analysis><citation_analysis attribute="neither"> However, children manifest significantly different NT1 symptoms compared to adults thus calling for specific evaluation approaches. Recently, Wang et al</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0115" ref-type="bibr">115</xref></citation_analysis><citation_analysis attribute="negative"> proposed a subjective sleepiness scale and a cataplexy diary for pediatric narcolepsy, and, although not yet validated, they have been already applied in a clinical trial.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0116" ref-type="bibr">116</xref></citation_analysis><citation_analysis attribute="neither"> There is an urgent need of new standardized assessment tolls of disease severity aimed at better following the disease course and documenting treatments’ effects.</citation_analysis></p>
          </sec>
        </sec>
      </sec>
    </sec>
    <sec id="s0004">
      <title>Conclusion</title>
      <p><citation_analysis attribute="neither">To date only symptomatic treatments are available for narcolepsy, with new drugs recently showing promising results;</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0004" ref-type="bibr">4</xref></citation_analysis><citation_analysis attribute="neither">,</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0019" ref-type="bibr">19</xref></citation_analysis><citation_analysis attribute="positive"> however, chronic pharmacological treatments met with frequent side effects and may not sufficiently impact on disease burden.</citation_analysis><citation_analysis attribute="positive"><xref rid="cit0021" ref-type="bibr">21</xref></citation_analysis><citation_analysis attribute="positive"> No disease-modifying cure is available, calling for future research on treatment strategies as well as on diagnostic approaches able to identify patients who will develop NT1 among those complaining only EDS. NT1 is considered an immune-mediated disease, nevertheless the absence of definitive proofs represents a limit to design targeted clinical trials on immunotherapy. To date, indeed, only case series and case reports are available. However, although not yet conclusive, the evidence gathered so far suggest that is the time for randomized, double-blind, placebo-controlled trials that would contribute to answer the question whether immunotherapy is useful in narcolepsy.</citation_analysis></p>
    </sec>
  </body>
  <back>
    <sec id="s0005" sec-type="COI-statement">
      <title>Disclosure</title>
      <p><citation_analysis attribute="neither">Maria Pia Giannoccaro and Fabio Pizza reports no conflicts of interest in this work. Rocco Liguori reports personal fees from Argenx, Biogen, Sanofi-Genzyme, Argon Healthcare s.r.l., Amicus Therapeutics s.r.l. and Alfasigma for Advisory Board consultancy and Lecture fees from Dynamicom Education, SIMG Service, Adnkronos Salute Unipersonale s.r.l. and DOC Congress s.r.l., outside the submitted work. Giuseppe Plazzi participated in advisory board for UCB Pharma, Idorsia, Jazz pharmaceuticals and Bioprojet.</citation_analysis></p>
    </sec>
    <ref-list>
      <title>References</title>
      <ref id="cit0001">
        <label>1.</label>
        <mixed-citation publication-type="book"><collab>Medicine AA of S</collab>. <source><italic toggle="yes">The International Classification of Sleep Disorders, Third Edition (ICSD-3)</italic></source>; <year>2014</year>. <comment>(Medicine AA of S, editor.)</comment></mixed-citation>
      </ref>
      <ref id="cit0002">
        <label>2.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Silber</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Krahn</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Olson</surname>
<given-names>EJ</given-names></string-name>, <string-name><surname>Pankratz</surname>
<given-names>VS</given-names></string-name>. <article-title>The epidemiology of narcolepsy in Olmsted County, Minnesota: a Population-Based Study</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2002</year>;<volume>25</volume>(<issue>2</issue>):<fpage>197</fpage>–<lpage>202</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/25.2.197</pub-id><pub-id pub-id-type="pmid">11902429</pub-id></mixed-citation>
      </ref>
      <ref id="cit0003">
        <label>3.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dye</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Gurbani</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Simakajornboon</surname>
<given-names>N</given-names></string-name>. <article-title>Epidemiology and pathophysiology of childhood narcolepsy</article-title>. <source><italic toggle="yes">Paediatr Respir Rev</italic></source>. <year>2018</year>;<volume>25</volume>:<fpage>14</fpage>–<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.prrv.2016.12.005</pub-id><pub-id pub-id-type="pmid">28108192</pub-id></mixed-citation>
      </ref>
      <ref id="cit0004">
        <label>4.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Szabo</surname>
<given-names>ST</given-names></string-name>, <string-name><surname>Thorpy</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Mayer</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Peever</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Kilduff</surname>
<given-names>TS</given-names></string-name>. <article-title>Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy</article-title>. <source><italic toggle="yes">Sleep Med Rev</italic></source>. <year>2018</year>;<volume>43</volume>:<fpage>23</fpage>–<lpage>36</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.smrv.2018.09.006</pub-id><pub-id pub-id-type="pmid">30503715</pub-id></mixed-citation>
      </ref>
      <ref id="cit0005">
        <label>5.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Thannickal</surname>
<given-names>TC</given-names></string-name>, <string-name><surname>Nienhuis</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Siegel</surname>
<given-names>JM</given-names></string-name>. <article-title>Localized loss of hypocretin (Orexin) cells in narcolepsy without cataplexy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2009</year>;<volume>32</volume>(<issue>8</issue>):<fpage>993</fpage>–<lpage>998</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/32.8.993</pub-id><pub-id pub-id-type="pmid">19725250</pub-id></mixed-citation>
      </ref>
      <ref id="cit0006">
        <label>6.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tabuchi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Tsunematsu</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Black</surname>
<given-names>SW</given-names></string-name>, et al. <article-title>Conditional ablation of orexin/hypocretin neurons: a New Mouse Model for the Study of Narcolepsy and Orexin System Function</article-title>. <source><italic toggle="yes">J Neurosci</italic></source>. <year>2014</year>;<volume>34</volume>(<issue>19</issue>):<fpage>6495</fpage>–<lpage>6509</lpage>. doi:<pub-id pub-id-type="doi">10.1523/jneurosci.0073-14.2014</pub-id><pub-id pub-id-type="pmid">24806676</pub-id></mixed-citation>
      </ref>
      <ref id="cit0007">
        <label>7.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Andlauer</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Moore</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Hong</surname>
<given-names>S-C</given-names></string-name>, et al. <article-title>Predictors of hypocretin (Orexin) deficiency in narcolepsy without cataplexy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2012</year>;<volume>35</volume>(<issue>9</issue>):<fpage>1247</fpage>–<lpage>1255</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.2080</pub-id><pub-id pub-id-type="pmid">22942503</pub-id></mixed-citation>
      </ref>
      <ref id="cit0008">
        <label>8.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Pizza</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Vandi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Liguori</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Primary progressive narcolepsy type 1: the other side of the coin</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2014</year>;<volume>83</volume>(<issue>23</issue>):<fpage>2189</fpage>–<lpage>2190</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.0000000000001051</pub-id><pub-id pub-id-type="pmid">25355832</pub-id></mixed-citation>
      </ref>
      <ref id="cit0009">
        <label>9.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lopez</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Barateau</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Evangelista</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Temporal changes in the cerebrospinal fluid level of hypocretin-1 and histamine in narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2017</year>;<volume>40</volume>(<issue>1</issue>). doi:<pub-id pub-id-type="doi">10.1093/sleep/zsw010</pub-id></mixed-citation>
      </ref>
      <ref id="cit0010">
        <label>10.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bonakis</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Howard</surname>
<given-names>RS</given-names></string-name>, <string-name><surname>Ebrahim</surname>
<given-names>IO</given-names></string-name>, <string-name><surname>Merritt</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Williams</surname>
<given-names>A</given-names></string-name>. <article-title>REM sleep behaviour disorder (RBD) and its associations in young patients</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2009</year>;<volume>10</volume>(<issue>6</issue>):<fpage>641</fpage>–<lpage>645</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2008.07.008</pub-id><pub-id pub-id-type="pmid">19109063</pub-id></mixed-citation>
      </ref>
      <ref id="cit0011">
        <label>11.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hublin</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Partinen</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kaprio</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Koskenvuo</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Guilleminault</surname>
<given-names>C</given-names></string-name>. <article-title>Epidemiology of narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>1994</year>;<volume>17</volume>(<issue>suppl_8</issue>):<fpage>S7</fpage>–<lpage>S12</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/17.suppl_8.s7</pub-id><pub-id pub-id-type="pmid">7701204</pub-id></mixed-citation>
      </ref>
      <ref id="cit0012">
        <label>12.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ohayon</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Priest</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Zulley</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Smirne</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Paiva</surname>
<given-names>T</given-names></string-name>. <article-title>Prevalence of narcolepsy symptomatology and diagnosis in the European general population</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2002</year>;<volume>58</volume>(<issue>12</issue>):<fpage>1826</fpage>–<lpage>1833</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.58.12.1826</pub-id><pub-id pub-id-type="pmid">12084885</pub-id></mixed-citation>
      </ref>
      <ref id="cit0013">
        <label>13.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Luca</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Haba-Rubio</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2013</year>;<volume>22</volume>(<issue>5</issue>):<fpage>482</fpage>–<lpage>495</lpage>. doi:<pub-id pub-id-type="doi">10.1111/jsr.12044</pub-id><pub-id pub-id-type="pmid">23496005</pub-id></mixed-citation>
      </ref>
      <ref id="cit0014">
        <label>14.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Thorpy</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Krieger</surname>
<given-names>AC</given-names></string-name>. <article-title>Delayed diagnosis of narcolepsy: characterization and impact</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>5</issue>):<fpage>502</fpage>–<lpage>507</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2014.01.015</pub-id><pub-id pub-id-type="pmid">24780133</pub-id></mixed-citation>
      </ref>
      <ref id="cit0015">
        <label>15.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dodel</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Peter</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Walbert</surname>
<given-names>T</given-names></string-name>, et al. <article-title>The socioeconomic impact of narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2004</year>;<volume>27</volume>(<issue>6</issue>):<fpage>1123</fpage>–<lpage>1128</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/27.6.1123</pub-id><pub-id pub-id-type="pmid">15532206</pub-id></mixed-citation>
      </ref>
      <ref id="cit0016">
        <label>16.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jennum</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ibsen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Petersen</surname>
<given-names>ER</given-names></string-name>, <string-name><surname>Knudsen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kjellberg</surname>
<given-names>J</given-names></string-name>. <article-title>Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2012</year>;<volume>13</volume>(<issue>8</issue>):<fpage>1086</fpage>–<lpage>1093</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2012.06.006</pub-id><pub-id pub-id-type="pmid">22841027</pub-id></mixed-citation>
      </ref>
      <ref id="cit0017">
        <label>17.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Black</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Reaven</surname>
<given-names>NL</given-names></string-name>, <string-name><surname>Funk</surname>
<given-names>SE</given-names></string-name>, et al. <article-title>The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2014</year>;<volume>15</volume>(<issue>5</issue>):<fpage>522</fpage>–<lpage>529</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2014.02.001</pub-id><pub-id pub-id-type="pmid">24768358</pub-id></mixed-citation>
      </ref>
      <ref id="cit0018">
        <label>18.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jennum</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Ibsen</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Knudsen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kjellberg</surname>
<given-names>J</given-names></string-name>. <article-title>Comorbidity and mortality of narcolepsy: a Controlled Retro- and Prospective National Study</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2013</year>;<volume>36</volume>(<issue>6</issue>):<fpage>835</fpage>–<lpage>840</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.2706</pub-id><pub-id pub-id-type="pmid">23729926</pub-id></mixed-citation>
      </ref>
      <ref id="cit0019">
        <label>19.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Abad</surname>
<given-names>VC</given-names></string-name>, <string-name><surname>Guilleminault</surname>
<given-names>C</given-names></string-name>. <article-title>New developments in the management of narcolepsy</article-title>. <source><italic toggle="yes">Nat Sci Sleep</italic></source>. <year>2017</year>;<volume>9</volume>:<fpage>39</fpage>–<lpage>57</lpage>. doi:<pub-id pub-id-type="doi">10.2147/nss.s103467</pub-id><pub-id pub-id-type="pmid">28424564</pub-id></mixed-citation>
      </ref>
      <ref id="cit0020">
        <label>20.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Thorpy</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>. <article-title>Clinical and practical considerations in the pharmacologic management of narcolepsy</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2015</year>;<volume>16</volume>(<issue>1</issue>):<fpage>9</fpage>–<lpage>18</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2014.10.002</pub-id><pub-id pub-id-type="pmid">25458251</pub-id></mixed-citation>
      </ref>
      <ref id="cit0021">
        <label>21.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Maski</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Steinhart</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Williams</surname>
<given-names>D</given-names></string-name>, et al. <article-title>Listening to the patient voice in narcolepsy: diagnostic delay, disease burden, and treatment efficacy</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2017</year>;<volume>13</volume>(<issue>03</issue>):<fpage>419</fpage>–<lpage>425</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.6494</pub-id><pub-id pub-id-type="pmid">27923434</pub-id></mixed-citation>
      </ref>
      <ref id="cit0022">
        <label>22.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kornum</surname>
<given-names>BR</given-names></string-name>. <article-title>Narcolepsy type 1: what have we learned from immunology?</article-title>
<source><italic toggle="yes">Sleep</italic></source>. <year>2020</year>;<volume>43</volume>(<issue>10</issue>). doi:<pub-id pub-id-type="doi">10.1093/sleep/zsaa055</pub-id></mixed-citation>
      </ref>
      <ref id="cit0023">
        <label>23.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Rose</surname>
<given-names>NR</given-names></string-name>, <string-name><surname>Bona</surname>
<given-names>C</given-names></string-name>. <article-title>Defining criteria for autoimmune diseases (Witebsky’s postulates revisited)</article-title>. <source><italic toggle="yes">Immunol Today</italic></source>. <year>1993</year>;<volume>14</volume>(<issue>9</issue>):<fpage>426</fpage>–<lpage>430</lpage>. doi:<pub-id pub-id-type="doi">10.1016/0167-5699(93)90244-f</pub-id><pub-id pub-id-type="pmid">8216719</pub-id></mixed-citation>
      </ref>
      <ref id="cit0024">
        <label>24.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Han</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Schormair</surname>
<given-names>B</given-names></string-name>, et al. <article-title>HLA DQB1*06:02 negative narcolepsy with hypocretin/orexin deficiency</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2014</year>;<volume>37</volume>(<issue>10</issue>):<fpage>1601</fpage>–<lpage>1608</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.4066</pub-id><pub-id pub-id-type="pmid">25197808</pub-id></mixed-citation>
      </ref>
      <ref id="cit0025">
        <label>25.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Arango</surname>
<given-names>M-T</given-names></string-name>, <string-name><surname>Kivity</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Shoenfeld</surname>
<given-names>Y</given-names></string-name>. <article-title>Is narcolepsy a classical autoimmune disease?</article-title>
<source><italic toggle="yes">Pharmacol Res</italic></source>. <year>2015</year>;<volume>92</volume>:<fpage>6</fpage>–<lpage>12</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.phrs.2014.10.005</pub-id><pub-id pub-id-type="pmid">25447795</pub-id></mixed-citation>
      </ref>
      <ref id="cit0026">
        <label>26.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Koepsell</surname>
<given-names>TD</given-names></string-name>, <string-name><surname>Longstreth</surname>
<given-names>WT</given-names></string-name>, <string-name><surname>Ton</surname>
<given-names>TGN</given-names></string-name>. <article-title>Medical exposures in youth and the frequency of narcolepsy with cataplexy: a population-based case–control study in genetically predisposed people</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2010</year>;<volume>19</volume>(<issue>1–Part–I</issue>):<fpage>80</fpage>–<lpage>86</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2869.2009.00756.x</pub-id><pub-id pub-id-type="pmid">19732319</pub-id></mixed-citation>
      </ref>
      <ref id="cit0027">
        <label>27.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Aran</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Nevsimalova</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2009</year>;<volume>32</volume>(<issue>8</issue>):<fpage>979</fpage>–<lpage>983</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/32.8.979</pub-id><pub-id pub-id-type="pmid">19725248</pub-id></mixed-citation>
      </ref>
      <ref id="cit0028">
        <label>28.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Han</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Warby</surname>
<given-names>SC</given-names></string-name>, et al. <article-title>Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in china</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2011</year>;<volume>70</volume>(<issue>3</issue>):<fpage>410</fpage>–<lpage>417</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.22587</pub-id><pub-id pub-id-type="pmid">21866560</pub-id></mixed-citation>
      </ref>
      <ref id="cit0029">
        <label>29.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Partinen</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Saarenpää-Heikkilä</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Ilveskoski</surname>
<given-names>I</given-names></string-name>, et al. <article-title>Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2012</year>;<volume>7</volume>(<issue>3</issue>):<fpage>e33723</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0033723</pub-id><pub-id pub-id-type="pmid">22470463</pub-id></mixed-citation>
      </ref>
      <ref id="cit0030">
        <label>30.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Szakács</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Darin</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Hallböök</surname>
<given-names>T</given-names></string-name>. <article-title>Increased childhood incidence of narcolepsy in western Sweden after H1N1 influenza vaccination</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2013</year>;<volume>80</volume>(<issue>14</issue>):<fpage>1315</fpage>–<lpage>1321</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.0b013e31828ab26f</pub-id><pub-id pub-id-type="pmid">23486871</pub-id></mixed-citation>
      </ref>
      <ref id="cit0031">
        <label>31.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wijnans</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Lecomte</surname>
<given-names>C</given-names></string-name>, <string-name><surname>de Vries</surname>
<given-names>C</given-names></string-name>, et al. <article-title>The incidence of narcolepsy in Europe: before, during, and after the influenza A(H1N1)pdm09 pandemic and vaccination campaigns</article-title>. <source><italic toggle="yes">Vaccine</italic></source>. <year>2013</year>;<volume>31</volume>(<issue>8</issue>):<fpage>1246</fpage>–<lpage>1254</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.vaccine.2012.12.015</pub-id><pub-id pub-id-type="pmid">23246544</pub-id></mixed-citation>
      </ref>
      <ref id="cit0032">
        <label>32.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Nohynek</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Jokinen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Partinen</surname>
<given-names>M</given-names></string-name>, et al. <article-title>AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2012</year>;<volume>7</volume>(<issue>3</issue>):<fpage>e33536</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0033536</pub-id><pub-id pub-id-type="pmid">22470453</pub-id></mixed-citation>
      </ref>
      <ref id="cit0033">
        <label>33.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Heier</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Gautvik</surname>
<given-names>KM</given-names></string-name>, <string-name><surname>Wannag</surname>
<given-names>E</given-names></string-name>, et al. <article-title>Incidence of narcolepsy in Norwegian children and adolescents after vaccination against H1N1 influenza A</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2013</year>;<volume>14</volume>(<issue>9</issue>):<fpage>867</fpage>–<lpage>871</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2013.03.020</pub-id><pub-id pub-id-type="pmid">23773727</pub-id></mixed-citation>
      </ref>
      <ref id="cit0034">
        <label>34.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Luo</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ambati</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Autoimmunity to hypocretin and molecular mimicry to flu in type 1 narcolepsy</article-title>. <source><italic toggle="yes">Proc Natl Acad Sci</italic></source>. <year>2018</year>;<volume>115</volume>(<issue>52</issue>):<fpage>201818150</fpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1818150116</pub-id></mixed-citation>
      </ref>
      <ref id="cit0035">
        <label>35.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Schinkelshoek</surname>
<given-names>MS</given-names></string-name>, <string-name><surname>Fronczek</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Kooy-Winkelaar</surname>
<given-names>EMC</given-names></string-name>, et al. <article-title>H1N1 hemagglutinin-specific HLA-DQ6-restricted CD4+ T cells can be readily detected in narcolepsy type 1 patients and healthy controls</article-title>. <source><italic toggle="yes">J Neuroimmunol</italic></source>. <year>2019</year>;<volume>332</volume>:<fpage>167</fpage>–<lpage>175</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jneuroim.2019.04.009</pub-id><pub-id pub-id-type="pmid">31048269</pub-id></mixed-citation>
      </ref>
      <ref id="cit0036">
        <label>36.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hallmayer</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Faraco</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Narcolepsy is strongly associated with the T-cell receptor alpha locus</article-title>. <source><italic toggle="yes">Nat Genet</italic></source>. <year>2009</year>;<volume>41</volume>(<issue>6</issue>):<fpage>708</fpage>–<lpage>711</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.372</pub-id><pub-id pub-id-type="pmid">19412176</pub-id></mixed-citation>
      </ref>
      <ref id="cit0037">
        <label>37.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kornum</surname>
<given-names>BR</given-names></string-name>, <string-name><surname>Kawashima</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Faraco</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Common variants in P2RY11 are associated with narcolepsy</article-title>. <source><italic toggle="yes">Nat Genet</italic></source>. <year>2011</year>;<volume>43</volume>(<issue>1</issue>):<fpage>66</fpage>–<lpage>71</lpage>. doi:<pub-id pub-id-type="doi">10.1038/ng.734</pub-id><pub-id pub-id-type="pmid">21170044</pub-id></mixed-citation>
      </ref>
      <ref id="cit0038">
        <label>38.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Han</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Faraco</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Dong</surname>
<given-names>XS</given-names></string-name>, et al. <article-title>Genome wide analysis of narcolepsy in China implicates novel immune Loci and Reveals Changes in Association prior to versus after the 2009 H1N1 influenza pandemic</article-title>. <source><italic toggle="yes">Plos Genet</italic></source>. <year>2013</year>;<volume>9</volume>(<issue>10</issue>):<fpage>e1003880</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pgen.1003880</pub-id><pub-id pub-id-type="pmid">24204295</pub-id></mixed-citation>
      </ref>
      <ref id="cit0039">
        <label>39.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Toyoda</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Miyagawa</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Koike</surname>
<given-names>A</given-names></string-name>, et al. <article-title>A polymorphism in CCR1/CCR3 is associated with narcolepsy</article-title>. <source><italic toggle="yes">Brain Behav Immun</italic></source>. <year>2015</year>;<volume>49</volume>:<fpage>148</fpage>–<lpage>155</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.bbi.2015.05.003</pub-id><pub-id pub-id-type="pmid">25986216</pub-id></mixed-citation>
      </ref>
      <ref id="cit0040">
        <label>40.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Faraco</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Kornum</surname>
<given-names>BR</given-names></string-name>, et al. <article-title>ImmunoChip Study implicates antigen presentation to T cells in narcolepsy</article-title>. <source><italic toggle="yes">Plos Genet</italic></source>. <year>2013</year>;<volume>9</volume>(<issue>2</issue>):<fpage>e1003270</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pgen.1003270</pub-id><pub-id pub-id-type="pmid">23459209</pub-id></mixed-citation>
      </ref>
      <ref id="cit0041">
        <label>41.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Latorre</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Kallweit</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Armentani</surname>
<given-names>E</given-names></string-name>, et al. <article-title>T cells in patients with narcolepsy target self-antigens of hypocretin neurons</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2018</year>;<volume>562</volume>(<issue>7725</issue>):<fpage>63</fpage>–<lpage>68</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41586-018-0540-1</pub-id><pub-id pub-id-type="pmid">30232458</pub-id></mixed-citation>
      </ref>
      <ref id="cit0042">
        <label>42.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cogswell</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Maski</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Scammell</surname>
<given-names>TE</given-names></string-name>, <string-name><surname>Tucker</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Orban</surname>
<given-names>ZS</given-names></string-name>, <string-name><surname>Koralnik</surname>
<given-names>IJ</given-names></string-name>. <article-title>Children with Narcolepsy type 1 have increased T-cell responses to orexins</article-title>. <source><italic toggle="yes">Ann Clin Transl Neurol</italic></source>. <year>2019</year>;<volume>6</volume>(<issue>12</issue>):<fpage>2566</fpage>–<lpage>2572</lpage>. doi:<pub-id pub-id-type="doi">10.1002/acn3.50908</pub-id><pub-id pub-id-type="pmid">31730293</pub-id></mixed-citation>
      </ref>
      <ref id="cit0043">
        <label>43.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Liblau</surname>
<given-names>RS</given-names></string-name>. <article-title>Put to sleep by immune cells</article-title>. <source><italic toggle="yes">Nature</italic></source>. <year>2018</year>;<volume>562</volume>(<issue>7725</issue>):<fpage>46</fpage>–<lpage>48</lpage>. doi:<pub-id pub-id-type="doi">10.1038/d41586-018-06666-w</pub-id><pub-id pub-id-type="pmid">30275550</pub-id></mixed-citation>
      </ref>
      <ref id="cit0044">
        <label>44.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tafti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lammers</surname>
<given-names>GJ</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Narcolepsy-Associated HLA class I alleles implicate cell-mediated cytotoxicity</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2016</year>;<volume>39</volume>(<issue>3</issue>):<fpage>581</fpage>–<lpage>587</lpage>. doi:<pub-id pub-id-type="doi">10.5665/sleep.5532</pub-id><pub-id pub-id-type="pmid">26518595</pub-id></mixed-citation>
      </ref>
      <ref id="cit0045">
        <label>45.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ollila</surname>
<given-names>HM</given-names></string-name>, <string-name><surname>Ravel</surname>
<given-names>J-M</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>F</given-names></string-name>, et al. <article-title>HLA-DPB1 and HLA class I confer risk of and protection from narcolepsy</article-title>. <source><italic toggle="yes">Am J Hum Genetics</italic></source>. <year>2015</year>;<volume>96</volume>(<issue>1</issue>):<fpage>136</fpage>–<lpage>146</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ajhg.2014.12.010</pub-id><pub-id pub-id-type="pmid">25574827</pub-id></mixed-citation>
      </ref>
      <ref id="cit0046">
        <label>46.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Degn</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Dreisig</surname>
<given-names>K</given-names></string-name>, et al. <article-title>Rare missense mutations in P2RY11 in narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2017</year>;<volume>140</volume>(<issue>6</issue>):<fpage>1657</fpage>–<lpage>1668</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awx093</pub-id><pub-id pub-id-type="pmid">28460015</pub-id></mixed-citation>
      </ref>
      <ref id="cit0047">
        <label>47.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Bauer</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Rigau</surname>
<given-names>V</given-names></string-name>, et al. <article-title>Hypothalamic immunopathology in anti-Ma–associated diencephalitis with narcolepsy-cataplexy</article-title>. <source><italic toggle="yes">JAMA Neurol</italic></source>. <year>2013</year>;<volume>70</volume>(<issue>10</issue>):<fpage>1305</fpage>–<lpage>1310</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jamaneurol.2013.2831</pub-id><pub-id pub-id-type="pmid">23939463</pub-id></mixed-citation>
      </ref>
      <ref id="cit0048">
        <label>48.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Bernard-Valnet</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Yshii</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Quériault</surname>
<given-names>C</given-names></string-name>, et al. <article-title>CD8 T cell-mediated killing of orexinergic neurons induces a narcolepsy-like phenotype in mice</article-title>. <source><italic toggle="yes">Proc Natl Acad Sci</italic></source>. <year>2016</year>;<volume>113</volume>(<issue>39</issue>):<fpage>10956</fpage>–<lpage>10961</lpage>. doi:<pub-id pub-id-type="doi">10.1073/pnas.1603325113</pub-id><pub-id pub-id-type="pmid">27621438</pub-id></mixed-citation>
      </ref>
      <ref id="cit0049">
        <label>49.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Pedersen</surname>
<given-names>NW</given-names></string-name>, <string-name><surname>Holm</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Kristensen</surname>
<given-names>NP</given-names></string-name>, et al. <article-title>CD8+ T cells from patients with narcolepsy and healthy controls recognize hypocretin neuron-specific antigens</article-title>. <source><italic toggle="yes">Nat Commun</italic></source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>837</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-08774-1</pub-id><pub-id pub-id-type="pmid">30783092</pub-id></mixed-citation>
      </ref>
      <ref id="cit0050">
        <label>50.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jiang</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Birtley</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Hung</surname>
<given-names>S-C</given-names></string-name>, et al. <article-title>In vivo clonal expansion and phenotypes of hypocretin-specific CD4+ T cells in narcolepsy patients and controls</article-title>. <source><italic toggle="yes">Nat Commun</italic></source>. <year>2019</year>;<volume>10</volume>(<issue>1</issue>):<fpage>5247</fpage>. doi:<pub-id pub-id-type="doi">10.1038/s41467-019-13234-x</pub-id><pub-id pub-id-type="pmid">31748512</pub-id></mixed-citation>
      </ref>
      <ref id="cit0051">
        <label>51.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lund</surname>
<given-names>FE</given-names></string-name>, <string-name><surname>Randall</surname>
<given-names>TD</given-names></string-name>. <article-title>Effector and regulatory B cells: modulators of CD4+ T cell immunity</article-title>. <source><italic toggle="yes">Nat Rev Immunol</italic></source>. <year>2010</year>;<volume>10</volume>(<issue>4</issue>):<fpage>236</fpage>–<lpage>247</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nri2729</pub-id><pub-id pub-id-type="pmid">20224569</pub-id></mixed-citation>
      </ref>
      <ref id="cit0052">
        <label>52.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Black</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Silber</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Krahn</surname>
<given-names>LE</given-names></string-name>, et al. <article-title>Analysis of Hypocretin (Orexin) antibodies in patients with narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2005</year>;<volume>28</volume>(<issue>4</issue>):<fpage>427</fpage>–<lpage>431</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/28.4.427</pub-id><pub-id pub-id-type="pmid">16171287</pub-id></mixed-citation>
      </ref>
      <ref id="cit0053">
        <label>53.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Tanaka</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Honda</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Inoue</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Honda</surname>
<given-names>M</given-names></string-name>. <article-title>Detection of autoantibodies against hypocretin, hcrtr1, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2006</year>;<volume>29</volume>(<issue>5</issue>):<fpage>633</fpage>–<lpage>638</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/29.5.633</pub-id><pub-id pub-id-type="pmid">16774153</pub-id></mixed-citation>
      </ref>
      <ref id="cit0054">
        <label>54.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Knudsen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mikkelsen</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Jennum</surname>
<given-names>P</given-names></string-name>. <article-title>Antibodies in narcolepsy–cataplexy patient serum bind to rat hypocretin neurons</article-title>. <source><italic toggle="yes">Neuroreport</italic></source>. <year>2007</year>;<volume>18</volume>(<issue>1</issue>):<fpage>77</fpage>–<lpage>79</lpage>. doi:<pub-id pub-id-type="doi">10.1097/wnr.0b013e328010baad</pub-id><pub-id pub-id-type="pmid">17259865</pub-id></mixed-citation>
      </ref>
      <ref id="cit0055">
        <label>55.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Martínez-Rodríguez</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Sabater</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Graus</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Iranzo</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Santamaria</surname>
<given-names>J</given-names></string-name>. <article-title>Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2007</year>;<volume>30</volume>(<issue>1</issue>):<fpage>27</fpage>–<lpage>28</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/30.1.27</pub-id><pub-id pub-id-type="pmid">17310861</pub-id></mixed-citation>
      </ref>
      <ref id="cit0056">
        <label>56.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Overeem</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Verschuuren</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Fronczek</surname>
<given-names>R</given-names></string-name>, et al. <article-title>Immunohistochemical screening for autoantibodies against lateral hypothalamic neurons in human narcolepsy</article-title>. <source><italic toggle="yes">J Neuroimmunol</italic></source>. <year>2006</year>;<volume>174</volume>(<issue>1–2</issue>):<fpage>187</fpage>–<lpage>191</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jneuroim.2006.02.010</pub-id><pub-id pub-id-type="pmid">16563524</pub-id></mixed-citation>
      </ref>
      <ref id="cit0057">
        <label>57.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Black</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Krahn</surname>
<given-names>LE</given-names></string-name>, <string-name><surname>Pankratz</surname>
<given-names>VS</given-names></string-name>, <string-name><surname>Silber</surname>
<given-names>M</given-names></string-name>. <article-title>Search for neuron-specific and nonneuron-specific antibodies in narcoleptic patients with and without HLA DQB1*0602</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2002</year>;<volume>25</volume>(<issue>7</issue>):<fpage>719</fpage>–<lpage>723</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/25.7.719</pub-id><pub-id pub-id-type="pmid">12405606</pub-id></mixed-citation>
      </ref>
      <ref id="cit0058">
        <label>58.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cvetkovic-Lopes</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Bayer</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Dorsaz</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Elevated tribbles homolog 2–specific antibody levels in narcolepsy patients</article-title>. <source><italic toggle="yes">J Clin Invest</italic></source>. <year>2010</year>;<volume>120</volume>(<issue>3</issue>):<fpage>713</fpage>–<lpage>719</lpage>. doi:<pub-id pub-id-type="doi">10.1172/jci41366</pub-id><pub-id pub-id-type="pmid">20160349</pub-id></mixed-citation>
      </ref>
      <ref id="cit0059">
        <label>59.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kawashima</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Tanaka</surname>
<given-names>S</given-names></string-name>, et al. <article-title>Anti-tribbles Homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2010</year>;<volume>33</volume>(<issue>7</issue>):<fpage>869</fpage>–<lpage>874</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/33.7.869</pub-id><pub-id pub-id-type="pmid">20614846</pub-id></mixed-citation>
      </ref>
      <ref id="cit0060">
        <label>60.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Toyoda</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Tanaka</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Miyagawa</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Honda</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tokunaga</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Honda</surname>
<given-names>M</given-names></string-name>. <article-title>Anti-tribbles Homolog 2 autoantibodies in Japanese patients with narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2010</year>;<volume>33</volume>(<issue>7</issue>):<fpage>875</fpage>–<lpage>878</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/33.7.875</pub-id><pub-id pub-id-type="pmid">20614847</pub-id></mixed-citation>
      </ref>
      <ref id="cit0061">
        <label>61.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lind</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Ramelius</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Olsson</surname>
<given-names>T</given-names></string-name>, et al. <article-title>A/H1N1 antibodies and TRIB2 autoantibodies in narcolepsy patients diagnosed in conjunction with the Pandemrix vaccination campaign in Sweden 2009–2010</article-title>. <source><italic toggle="yes">J Autoimmun</italic></source>. <year>2014</year>;<volume>50</volume>:<fpage>99</fpage>–<lpage>106</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jaut.2014.01.031</pub-id><pub-id pub-id-type="pmid">24485154</pub-id></mixed-citation>
      </ref>
      <ref id="cit0062">
        <label>62.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ahmed</surname>
<given-names>SS</given-names></string-name>, <string-name><surname>Volkmuth</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Duca</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Antibodies to influenza nucleoprotein cross-react with human hypocretin receptor 2</article-title>. <source><italic toggle="yes">Sci Transl Med</italic></source>. <year>2015</year>;<volume>7</volume>(<issue>294</issue>):<fpage>294ra105</fpage>. doi:<pub-id pub-id-type="doi">10.1126/scitranslmed.aab2354</pub-id></mixed-citation>
      </ref>
      <ref id="cit0063">
        <label>63.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Giannoccaro</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Waters</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Pizza</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Liguori</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Plazzi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Vincent</surname>
<given-names>A</given-names></string-name>. <article-title>Antibodies against Hypocretin receptor 2 are rare in narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2016</year>;<volume>40</volume>(<issue>2</issue>). doi:<pub-id pub-id-type="doi">10.1093/sleep/zsw056</pub-id></mixed-citation>
      </ref>
      <ref id="cit0064">
        <label>64.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Luo</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Jacob</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Absence of anti-hypocretin receptor 2 autoantibodies in post pandemrix narcolepsy cases</article-title>. <source><italic toggle="yes">PLoS One</italic></source>. <year>2017</year>;<volume>12</volume>(<issue>12</issue>):<fpage>e0187305</fpage>. doi:<pub-id pub-id-type="doi">10.1371/journal.pone.0187305</pub-id><pub-id pub-id-type="pmid">29220370</pub-id></mixed-citation>
      </ref>
      <ref id="cit0065">
        <label>65.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Giannoccaro</surname>
<given-names>MP</given-names></string-name>, <string-name><surname>Pizza</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Jacobson</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Liguori</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Plazzi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Vincent</surname>
<given-names>A</given-names></string-name>. <article-title>Neuronal surface antibodies are common in children with narcolepsy and active movement disorders</article-title>. <source><italic toggle="yes">J Neurol Neurosurg Psychiatry</italic></source>. <year>2020</year>:<page-range>jnnp-2020-323638</page-range>. doi:<pub-id pub-id-type="doi">10.1136/jnnp-2020-323638</pub-id></mixed-citation>
      </ref>
      <ref id="cit0066">
        <label>66.</label>
        <mixed-citation publication-type="book"><string-name><surname>Chatman</surname>
<given-names>WW</given-names></string-name>. <chapter-title>Glucocorticoid effects on the immune system</chapter-title>. In: <string-name><surname>Orange</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Marr</surname>
<given-names>KA</given-names></string-name>, <string-name><surname>Feldweg</surname>
<given-names>AM</given-names></string-name>, <string-name><surname>Bond</surname>
<given-names>S</given-names></string-name>, editors. <source><italic toggle="yes">Uptodate</italic></source>; <year>2020</year>. Uptodate (Accessed February 11, 2021).</mixed-citation>
      </ref>
      <ref id="cit0067">
        <label>67.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Hecht</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Kushida</surname>
<given-names>CA</given-names></string-name>, et al. <article-title>Report of a case of immunosuppression with prednisone in an 8-year-old boy with an acute onset of hypocretin-deficiency narcolepsy</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2003</year>;<volume>26</volume>(<issue>7</issue>):<fpage>809</fpage>–<lpage>810</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/26.7.809</pub-id><pub-id pub-id-type="pmid">14655912</pub-id></mixed-citation>
      </ref>
      <ref id="cit0068">
        <label>68.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Peraita-Adrados</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Romero-Martínez</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Guzmán-de Villoria</surname>
<given-names>JA</given-names></string-name>, <string-name><surname>Lillo-Triguero</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Martínez-Ginés</surname>
<given-names>ML</given-names></string-name>. <article-title>Comorbidity of narcolepsy with cataplexy and transverse myelitis: a common autoimmune background? A case report</article-title>. <source><italic toggle="yes">Sleep Med</italic></source>. <year>2017</year>;<volume>33</volume>:<fpage>167</fpage>–<lpage>170</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.sleep.2017.02.014</pub-id><pub-id pub-id-type="pmid">28449899</pub-id></mixed-citation>
      </ref>
      <ref id="cit0069">
        <label>69.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Coelho</surname>
<given-names>FMS</given-names></string-name>, <string-name><surname>Pradella-Hallinan</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Alves</surname>
<given-names>GR</given-names></string-name>, <string-name><surname>Bittencourt</surname>
<given-names>LRA</given-names></string-name>, <string-name><surname>Tufik</surname>
<given-names>S</given-names></string-name>. <article-title>Report of two narcoleptic patients with remission of hypersomnolence following use of prednisone</article-title>. <source><italic toggle="yes">Arq Neuropsiquiatr</italic></source>. <year>2007</year>;<volume>65</volume>(<issue>2A</issue>):<fpage>336</fpage>–<lpage>337</lpage>. doi:<pub-id pub-id-type="doi">10.1590/s0004-282x2007000200028</pub-id><pub-id pub-id-type="pmid">17607439</pub-id></mixed-citation>
      </ref>
      <ref id="cit0070">
        <label>70.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lecendreux</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Maret</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bassetti</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Mouren</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Tafti</surname>
<given-names>M</given-names></string-name>. <article-title>Clinical efficacy of high-dose intravenous immunoglobulins near the onset of narcolepsy in a 10-year-old boy</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2003</year>;<volume>12</volume>(<issue>4</issue>):<fpage>347</fpage>–<lpage>348</lpage>. doi:<pub-id pub-id-type="doi">10.1046/j.1365-2869.2003.00380.x</pub-id><pub-id pub-id-type="pmid">14633248</pub-id></mixed-citation>
      </ref>
      <ref id="cit0071">
        <label>71.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Viste</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Soosai</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Vikin</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Thorsby</surname>
<given-names>PM</given-names></string-name>, <string-name><surname>Nilsen</surname>
<given-names>KB</given-names></string-name>, <string-name><surname>Knudsen</surname>
<given-names>S</given-names></string-name>. <article-title>Long-term improvement after combined immunomodulation in early post-H1N1 vaccination narcolepsy</article-title>. <source><italic toggle="yes">Neurol Neuroimmunol Neuroinflamm</italic></source>. <year>2017</year>;<volume>4</volume>(<issue>5</issue>):<fpage>e389</fpage>. doi:<pub-id pub-id-type="doi">10.1212/nxi.0000000000000389</pub-id><pub-id pub-id-type="pmid">28840177</pub-id></mixed-citation>
      </ref>
      <ref id="cit0072">
        <label>72.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fietta</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Fietta</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Delsante</surname>
<given-names>G</given-names></string-name>. <article-title>Central nervous system effects of natural and synthetic glucocorticoids</article-title>. <source><italic toggle="yes">Psychiatry Clin Neurosci</italic></source>. <year>2009</year>;<volume>63</volume>(<issue>5</issue>):<fpage>613</fpage>–<lpage>622</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1440-1819.2009.02005.x</pub-id><pub-id pub-id-type="pmid">19788629</pub-id></mixed-citation>
      </ref>
      <ref id="cit0073">
        <label>73.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Krugers</surname>
<given-names>HJ</given-names></string-name>, <string-name><surname>Karst</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Joels</surname>
<given-names>M</given-names></string-name>. <article-title>Interactions between noradrenaline and corticosteroids in the brain: from electrical activity to cognitive performance</article-title>. <source><italic toggle="yes">Front Cell Neurosci</italic></source>. <year>2012</year>;<volume>6</volume>:<fpage>15</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fncel.2012.00015</pub-id><pub-id pub-id-type="pmid">22509154</pub-id></mixed-citation>
      </ref>
      <ref id="cit0074">
        <label>74.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Chen</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Black</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Call</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mignot</surname>
<given-names>E</given-names></string-name>. <article-title>Late-onset narcolepsy presenting as rapidly progressing muscle weakness: response to plasmapheresis</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2005</year>;<volume>58</volume>(<issue>3</issue>):<fpage>489</fpage>–<lpage>490</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.20603</pub-id><pub-id pub-id-type="pmid">16130098</pub-id></mixed-citation>
      </ref>
      <ref id="cit0075">
        <label>75.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Carlander</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Touchon</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Tafti</surname>
<given-names>M</given-names></string-name>. <article-title>Successful management of cataplexy with intravenous immunoglobulins at narcolepsy onset</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2004</year>;<volume>56</volume>(<issue>6</issue>):<fpage>905</fpage>–<lpage>908</lpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.20339</pub-id><pub-id pub-id-type="pmid">15562415</pub-id></mixed-citation>
      </ref>
      <ref id="cit0076">
        <label>76.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>. <article-title>Follow-up of four narcolepsy patients treated with intravenous immunoglobulins</article-title>. <source><italic toggle="yes">Ann Neurol</italic></source>. <year>2006</year>;<volume>60</volume>(<issue>1</issue>):<fpage>153</fpage>. doi:<pub-id pub-id-type="doi">10.1002/ana.20892</pub-id><pub-id pub-id-type="pmid">16802296</pub-id></mixed-citation>
      </ref>
      <ref id="cit0077">
        <label>77.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Abril</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Mas</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Michel</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Tafti</surname>
<given-names>M</given-names></string-name>. <article-title>Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2009</year>;<volume>73</volume>(<issue>16</issue>):<fpage>1333</fpage>–<lpage>1334</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.0b013e3181bd1344</pub-id><pub-id pub-id-type="pmid">19841387</pub-id></mixed-citation>
      </ref>
      <ref id="cit0078">
        <label>78.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ruppert</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Zagala</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Chambe</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Intravenous immunoglobulin therapy administered early after narcolepsy type 1 onset in three patients evaluated by clinical and polysomnographic follow-up</article-title>. <source><italic toggle="yes">Behav Neurol</italic></source>. <year>2018</year>;<volume>2018</volume>:<fpage>1</fpage>–<lpage>5</lpage>. doi:<pub-id pub-id-type="doi">10.1155/2018/1671072</pub-id></mixed-citation>
      </ref>
      <ref id="cit0079">
        <label>79.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Moreno-Estébanez</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Villabeitia</surname>
<given-names>IB</given-names></string-name>, <string-name><surname>Guibert</surname>
<given-names>TE</given-names></string-name>, et al. <article-title>Positive oligoclonal bands and CSF pleocytosis in narcolepsy type 1: a case report supporting the immune-mediated hypothesis</article-title>. <source><italic toggle="yes">J Neuroimmunol</italic></source>. <year>2019</year>;<volume>339</volume>:<fpage>577111</fpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jneuroim.2019.577111</pub-id><pub-id pub-id-type="pmid">31756639</pub-id></mixed-citation>
      </ref>
      <ref id="cit0080">
        <label>80.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Plazzi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Poli</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Franceschini</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Intravenous high-dose immunoglobulin treatment in recent onset childhood narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">J Neurol</italic></source>. <year>2008</year>;<volume>255</volume>(<issue>10</issue>):<fpage>1549</fpage>–<lpage>1554</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-008-0983-7</pub-id><pub-id pub-id-type="pmid">18769859</pub-id></mixed-citation>
      </ref>
      <ref id="cit0081">
        <label>81.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Knudsen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Mikkelsen</surname>
<given-names>JD</given-names></string-name>, <string-name><surname>Bang</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Gammeltoft</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jennum</surname>
<given-names>PJ</given-names></string-name>. <article-title>Intravenous immunoglobulin treatment and screening for hypocretin neuron-specific autoantibodies in recent onset childhood narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">Neuropediatrics</italic></source>. <year>2010</year>;<volume>41</volume>(<issue>05</issue>):<fpage>217</fpage>–<lpage>222</lpage>. doi:<pub-id pub-id-type="doi">10.1055/s-0030-1267993</pub-id><pub-id pub-id-type="pmid">21210337</pub-id></mixed-citation>
      </ref>
      <ref id="cit0082">
        <label>82.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Seong</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>Hong</surname>
<given-names>SB</given-names></string-name>. <article-title>Autoimmunity and immunotherapy in narcolepsy</article-title>. <source><italic toggle="yes">Sleep Med Res</italic></source>. <year>2017</year>;<volume>8</volume>(<issue>1</issue>):<fpage>1</fpage>–<lpage>7</lpage>. doi:<pub-id pub-id-type="doi">10.17241/smr.2017.00052</pub-id></mixed-citation>
      </ref>
      <ref id="cit0083">
        <label>83.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Valko</surname>
<given-names>PO</given-names></string-name>, <string-name><surname>Khatami</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Baumann</surname>
<given-names>CR</given-names></string-name>, <string-name><surname>Bassetti</surname>
<given-names>CL</given-names></string-name>. <article-title>No persistent effect of intravenous immunoglobulins in patients with narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">J Neurol</italic></source>. <year>2008</year>;<volume>255</volume>(<issue>12</issue>):<fpage>1900</fpage>–<lpage>1903</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-008-0996-2</pub-id><pub-id pub-id-type="pmid">18825431</pub-id></mixed-citation>
      </ref>
      <ref id="cit0084">
        <label>84.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Fronczek</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Verschuuren</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lammers</surname>
<given-names>GJ</given-names></string-name>. <article-title>Response to intravenous immunoglobulins and placebo in a patient with narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">J Neurol</italic></source>. <year>2007</year>;<volume>254</volume>(<issue>11</issue>):<fpage>1607</fpage>–<lpage>1608</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-007-0594-8</pub-id><pub-id pub-id-type="pmid">17762946</pub-id></mixed-citation>
      </ref>
      <ref id="cit0085">
        <label>85.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Lecendreux</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Berthier</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Corny</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bourdon</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Dossier</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Delclaux</surname>
<given-names>C</given-names></string-name>. <article-title>Intravenous immunoglobulin therapy in pediatric narcolepsy: a Nonrandomized, Open-Label, Controlled, Longitudinal Observational Study</article-title>. <source><italic toggle="yes">J Clin Sleep Med</italic></source>. <year>2017</year>;<volume>13</volume>(<issue>03</issue>):<fpage>441</fpage>–<lpage>453</lpage>. doi:<pub-id pub-id-type="doi">10.5664/jcsm.6500</pub-id><pub-id pub-id-type="pmid">28095967</pub-id></mixed-citation>
      </ref>
      <ref id="cit0086">
        <label>86.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Pizza</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Franceschini</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Peltola</surname>
<given-names>H</given-names></string-name>, et al. <article-title>Clinical and polysomnographic course of childhood narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2013</year>;<volume>136</volume>(<issue>12</issue>):<fpage>3787</fpage>–<lpage>3795</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awt277</pub-id><pub-id pub-id-type="pmid">24142146</pub-id></mixed-citation>
      </ref>
      <ref id="cit0087">
        <label>87.</label>
        <mixed-citation publication-type="book">Passouant P.  Billiard M. The evolution of narcolepsy with age. In: Guilleminault C, Dement WC, Passouant, P, editors. Narcolepsy. New York: Spectrum; 1976:179–197.</mixed-citation>
      </ref>
      <ref id="cit0088">
        <label>88.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Büchele</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Baumann</surname>
<given-names>CR</given-names></string-name>, <string-name><surname>Poryazova</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Werth</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Valko</surname>
<given-names>PO</given-names></string-name>. <article-title>Remitting narcolepsy? Longitudinal observations in a hypocretin-deficient cohort</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2018</year>;<volume>41</volume>(<issue>9</issue>):<fpage>zsy118</fpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/zsy118</pub-id></mixed-citation>
      </ref>
      <ref id="cit0089">
        <label>89.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Knudsen</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Biering-Sørensen</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kornum</surname>
<given-names>BR</given-names></string-name>, et al. <article-title>Early IVIg treatment has no effect on post-H1N1 narcolepsy phenotype or hypocretin deficiency</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2012</year>;<volume>79</volume>(<issue>1</issue>):<fpage>102</fpage>–<lpage>103</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.0b013e31825dce03</pub-id><pub-id pub-id-type="pmid">22722630</pub-id></mixed-citation>
      </ref>
      <ref id="cit0090">
        <label>90.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Sarkanen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Alén</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Partinen</surname>
<given-names>M</given-names></string-name>. <article-title>Transient impact of rituximab in H1N1 vaccination–associated narcolepsy with severe psychiatric symptoms</article-title>. <source><italic toggle="yes">Neurologist</italic></source>. <year>2016</year>;<volume>21</volume>(<issue>5</issue>):<fpage>85</fpage>–<lpage>86</lpage>. doi:<pub-id pub-id-type="doi">10.1097/nrl.0000000000000099</pub-id><pub-id pub-id-type="pmid">27564078</pub-id></mixed-citation>
      </ref>
      <ref id="cit0091">
        <label>91.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wasling</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Malmeström</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Blennow</surname>
<given-names>K</given-names></string-name>. <article-title>CSF orexin-A levels after rituximab treatment in recent onset narcolepsy type 1</article-title>. <source><italic toggle="yes">Neurol Neuroimmunol Neuroinflamm</italic></source>. <year>2019</year>;<volume>6</volume>(<issue>6</issue>):<fpage>e613</fpage>. doi:<pub-id pub-id-type="doi">10.1212/nxi.0000000000000613</pub-id><pub-id pub-id-type="pmid">31484686</pub-id></mixed-citation>
      </ref>
      <ref id="cit0092">
        <label>92.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ding</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Xiao</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Dong</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Han</surname>
<given-names>F</given-names></string-name>. <article-title>Treatment with immune modulators in a child with recent-onset type 1 narcolepsy</article-title>. <source><italic toggle="yes">Sleep Breath</italic></source>. <year>2020</year>;<fpage>1</fpage>–<lpage>3</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11325-020-02034-z</pub-id></mixed-citation>
      </ref>
      <ref id="cit0093">
        <label>93.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Donjacour</surname>
<given-names>CEHM</given-names></string-name>, <string-name><surname>Lammers</surname>
<given-names>GJ</given-names></string-name>. <article-title>A remarkable effect of alemtuzumab in a patient suffering from narcolepsy with cataplexy</article-title>. <source><italic toggle="yes">J Sleep Res</italic></source>. <year>2012</year>;<volume>21</volume>(<issue>4</issue>):<fpage>479</fpage>–<lpage>480</lpage>. doi:<pub-id pub-id-type="doi">10.1111/j.1365-2869.2011.00985.x</pub-id><pub-id pub-id-type="pmid">22142323</pub-id></mixed-citation>
      </ref>
      <ref id="cit0094">
        <label>94.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Guarnera</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Bramanti</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Mazzon</surname>
<given-names>E</given-names></string-name>. <article-title>Alemtuzumab: a review of efficacy and risks in the treatment of relapsing remitting multiple sclerosis</article-title>. <source><italic toggle="yes">Ther Clin Risk Manag</italic></source>. <year>2017</year>;<volume>13</volume>:<fpage>871</fpage>–<lpage>879</lpage>. doi:<pub-id pub-id-type="doi">10.2147/tcrm.s134398</pub-id><pub-id pub-id-type="pmid">28761351</pub-id></mixed-citation>
      </ref>
      <ref id="cit0095">
        <label>95.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Cronstein</surname>
<given-names>BN</given-names></string-name>, <string-name><surname>Aune</surname>
<given-names>TM</given-names></string-name>. <article-title>Methotrexate and its mechanisms of action in inflammatory arthritis</article-title>. <source><italic toggle="yes">Nat Rev Rheumatol</italic></source>. <year>2020</year>;<volume>16</volume>(<issue>3</issue>):<fpage>145</fpage>–<lpage>154</lpage>. doi:<pub-id pub-id-type="doi">10.1038/s41584-020-0373-9</pub-id><pub-id pub-id-type="pmid">32066940</pub-id></mixed-citation>
      </ref>
      <ref id="cit0096">
        <label>96.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Jones</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Anderson</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Phuah</surname>
<given-names>CL</given-names></string-name>, et al. <article-title>Improvement in disability after alemtuzumab treatment of multiple sclerosis is associated with neuroprotective autoimmunity</article-title>. <source><italic toggle="yes">Brain</italic></source>. <year>2010</year>;<volume>133</volume>(<issue>Pt 8</issue>):<fpage>2232</fpage>–<lpage>2247</lpage>. doi:<pub-id pub-id-type="doi">10.1093/brain/awq176</pub-id><pub-id pub-id-type="pmid">20659956</pub-id></mixed-citation>
      </ref>
      <ref id="cit0097">
        <label>97.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kallweit</surname>
<given-names>U</given-names></string-name>, <string-name><surname>Bassetti</surname>
<given-names>CLA</given-names></string-name>, <string-name><surname>Oberholzer</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Coexisting narcolepsy (with and without cataplexy) and multiple sclerosis</article-title>. <source><italic toggle="yes">J Neurol</italic></source>. <year>2018</year>;<volume>265</volume>(<issue>9</issue>):<fpage>2071</fpage>–<lpage>2078</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00415-018-8949-x</pub-id><pub-id pub-id-type="pmid">29974206</pub-id></mixed-citation>
      </ref>
      <ref id="cit0098">
        <label>98.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Vrethem</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Malmgren</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lindh</surname>
<given-names>J</given-names></string-name>. <article-title>A patient with both narcolepsy and multiple sclerosis in association with pandemrix vaccination</article-title>. <source><italic toggle="yes">J Neurol Sci</italic></source>. <year>2012</year>;<volume>321</volume>(<issue>1–2</issue>):<fpage>89</fpage>–<lpage>91</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jns.2012.07.025</pub-id><pub-id pub-id-type="pmid">22841884</pub-id></mixed-citation>
      </ref>
      <ref id="cit0099">
        <label>99.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Penner</surname>
<given-names>I-K</given-names></string-name>, <string-name><surname>Sivertsdotter</surname>
<given-names>EC</given-names></string-name>, <string-name><surname>Celius</surname>
<given-names>EG</given-names></string-name>, et al. <article-title>Improvement in fatigue during natalizumab treatment is linked to improvement in depression and day-time sleepiness</article-title>. <source><italic toggle="yes">Front Neurol</italic></source>. <year>2015</year>;<volume>6</volume>:<fpage>18</fpage>. doi:<pub-id pub-id-type="doi">10.3389/fneur.2015.00018</pub-id><pub-id pub-id-type="pmid">25755648</pub-id></mixed-citation>
      </ref>
      <ref id="cit0100">
        <label>100.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Sater</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Gudesblatt</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kresa-Reahl</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Brandes</surname>
<given-names>DW</given-names></string-name>, <string-name><surname>Sater</surname>
<given-names>P</given-names></string-name>. <article-title>NAPS-MS: natalizumab effects on parameters of sleep in multiple sclerosis patients</article-title>. <source><italic toggle="yes">Int J Ms Care</italic></source>. <year>2015</year>;<volume>18</volume>(<issue>4</issue>):<fpage>177</fpage>–<lpage>182</lpage>. doi:<pub-id pub-id-type="doi">10.7224/1537-2073.2015-033</pub-id></mixed-citation>
      </ref>
      <ref id="cit0101">
        <label>101.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Scammell</surname>
<given-names>TE</given-names></string-name>, <string-name><surname>Luo</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Borker</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Sullivan</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Biddle</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Mignot</surname>
<given-names>E</given-names></string-name>. <article-title>Treatment of narcolepsy with natalizumab</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2020</year>;<volume>43</volume>(<issue>7</issue>). doi:<pub-id pub-id-type="doi">10.1093/sleep/zsaa050</pub-id></mixed-citation>
      </ref>
      <ref id="cit0102">
        <label>102.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Emadi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Brodsky</surname>
<given-names>RA</given-names></string-name>. <article-title>Cyclophosphamide and cancer: golden anniversary</article-title>. <source><italic toggle="yes">Nat Rev Clin Oncol</italic></source>. <year>2009</year>;<volume>6</volume>(<issue>11</issue>):<fpage>638</fpage>–<lpage>647</lpage>. doi:<pub-id pub-id-type="doi">10.1038/nrclinonc.2009.146</pub-id><pub-id pub-id-type="pmid">19786984</pub-id></mixed-citation>
      </ref>
      <ref id="cit0103">
        <label>103.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Sistigu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Viaud</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chaput</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Bracci</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Proietti</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Zitvogel</surname>
<given-names>L</given-names></string-name>. <article-title>Immunomodulatory effects of cyclophosphamide and implementations for vaccine design</article-title>. <source><italic toggle="yes">Semin Immunopathol</italic></source>. <year>2011</year>;<volume>33</volume>(<issue>4</issue>):<fpage>369</fpage>–<lpage>383</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00281-011-0245-0</pub-id><pub-id pub-id-type="pmid">21611872</pub-id></mixed-citation>
      </ref>
      <ref id="cit0104">
        <label>104.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Ahlmann</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Hempel</surname>
<given-names>G</given-names></string-name>. <article-title>The effect of cyclophosphamide on the immune system: implications for clinical cancer therapy</article-title>. <source><italic toggle="yes">Cancer Chemother Pharmacol</italic></source>. <year>2016</year>;<volume>78</volume>(<issue>4</issue>):<fpage>661</fpage>–<lpage>671</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s00280-016-3152-1</pub-id><pub-id pub-id-type="pmid">27646791</pub-id></mixed-citation>
      </ref>
      <ref id="cit0105">
        <label>105.</label>
        <mixed-citation publication-type="book"><string-name><surname>McCune</surname>
<given-names>WJ</given-names></string-name>, <string-name><surname>Clowse</surname>
<given-names>MB</given-names></string-name>. <chapter-title>General principles of the use of cyclophosphamide in rheumatic diseases</chapter-title>. In: <string-name><surname>Furst</surname>
<given-names>DE</given-names></string-name>, <string-name><surname>Curtis</surname>
<given-names>MR</given-names></string-name>, editors. <source><italic toggle="yes">Uptodate</italic></source>; <year>2020</year>. Uptodate (Accessed February 11, 2021).</mixed-citation>
      </ref>
      <ref id="cit0106">
        <label>106.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Haddad</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Anouti</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Maalouly</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Koussa</surname>
<given-names>S</given-names></string-name>. <article-title>Narcolepsierévélant un lupus érythémateuxsystémique [Narcolepsy associated with systemic lupus erythematosus]</article-title>. <source><italic toggle="yes">Rev Med Interne</italic></source>. <year>2011</year>;<volume>32</volume>(<issue>11</issue>):<fpage>e114</fpage>–<lpage>5</lpage>. <comment>French</comment>. doi:<pub-id pub-id-type="doi">10.1016/j.revmed.2010.10.352</pub-id><pub-id pub-id-type="pmid">21145142</pub-id></mixed-citation>
      </ref>
      <ref id="cit0107">
        <label>107.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Adams</surname>
<given-names>C</given-names></string-name>, <string-name><surname>McKeon</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Silber</surname>
<given-names>MH</given-names></string-name>, <string-name><surname>Kumar</surname>
<given-names>R</given-names></string-name>. <article-title>Narcolepsy, REM sleep behavior disorder, and supranuclear gaze palsy associated with Ma1 and Ma2 antibodies and tonsillar carcinoma</article-title>. <source><italic toggle="yes">Arch Neurol</italic></source>. <year>2011</year>;<volume>68</volume>(<issue>4</issue>):<fpage>521</fpage>–<lpage>524</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archneurol.2011.56</pub-id><pub-id pub-id-type="pmid">21482933</pub-id></mixed-citation>
      </ref>
      <ref id="cit0108">
        <label>108.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Sinsioco</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Silver</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Forrest</surname>
<given-names>KM</given-names></string-name>, et al. <article-title>Narcolepsy with cataplexy as presenting symptom of occult neuroblastoma</article-title>. <source><italic toggle="yes">Pediatr Neurol</italic></source>. <year>2013</year>;<volume>49</volume>(<issue>1</issue>):<fpage>64</fpage>–<lpage>67</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.pediatrneurol.2012.12.038</pub-id><pub-id pub-id-type="pmid">23827430</pub-id></mixed-citation>
      </ref>
      <ref id="cit0109">
        <label>109.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Peters</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Vijiaratnam</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Lo</surname>
<given-names>KY</given-names></string-name>, <string-name><surname>Evans</surname>
<given-names>AH</given-names></string-name>. <article-title>Anti-Ma2-associated paraneoplastic encephalitis eat, sleep and repeat</article-title>. <source><italic toggle="yes">Intern Med J</italic></source>. <year>2019</year>;<volume>49</volume>(<issue>7</issue>):<fpage>931</fpage>–<lpage>932</lpage>. doi:<pub-id pub-id-type="doi">10.1111/imj.14349</pub-id><pub-id pub-id-type="pmid">31295780</pub-id></mixed-citation>
      </ref>
      <ref id="cit0110">
        <label>110.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Landolfi</surname>
<given-names>JC</given-names></string-name>, <string-name><surname>Nadkarni</surname>
<given-names>M</given-names></string-name>. <article-title>Paraneoplastic limbic encephalitis and possible narcolepsy in a patient with testicular cancer: case study</article-title>. <source><italic toggle="yes">Neuro Oncol</italic></source>. <year>2003</year>;<volume>5</volume>(<issue>3</issue>):<fpage>214</fpage>–<lpage>216</lpage>. doi:<pub-id pub-id-type="doi">10.1215/S1152851702000467</pub-id><pub-id pub-id-type="pmid">12816728</pub-id></mixed-citation>
      </ref>
      <ref id="cit0111">
        <label>111.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Berger</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Malik</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Lacey</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Brunetta</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lehane</surname>
<given-names>PB</given-names></string-name>. <article-title>Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event</article-title>. <source><italic toggle="yes">J Neurovirol</italic></source>. <year>2018</year>;<volume>24</volume>(<issue>3</issue>):<fpage>323</fpage>–<lpage>331</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13365-018-0615-7</pub-id><pub-id pub-id-type="pmid">29508305</pub-id></mixed-citation>
      </ref>
      <ref id="cit0112">
        <label>112.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Gerashchenko</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Murillo-Rodriguez</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Lin</surname>
<given-names>L</given-names></string-name>, et al. <article-title>Relationship between CSF hypocretin levels and hypocretin neuronal loss</article-title>. <source><italic toggle="yes">Exp Neurol</italic></source>. <year>2003</year>;<volume>184</volume>(<issue>2</issue>):<fpage>1010</fpage>–<lpage>1016</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s0014-4886(03)00388-1</pub-id><pub-id pub-id-type="pmid">14769395</pub-id></mixed-citation>
      </ref>
      <ref id="cit0113">
        <label>113.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Kubota</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Kanbayashi</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Tanabe</surname>
<given-names>Y</given-names></string-name>, et al. <article-title>Decreased cerebrospinal fluid hypocretin-1 levels near the onset of narcolepsy in 2 prepubertal children</article-title>. <source><italic toggle="yes">Sleep</italic></source>. <year>2003</year>;<volume>26</volume>(<issue>5</issue>):<fpage>555</fpage>–<lpage>557</lpage>. doi:<pub-id pub-id-type="doi">10.1093/sleep/26.5.555</pub-id><pub-id pub-id-type="pmid">12938807</pub-id></mixed-citation>
      </ref>
      <ref id="cit0114">
        <label>114.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Dauvilliers</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Beziat</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Pesenti</surname>
<given-names>C</given-names></string-name>, et al. <article-title>Measurement of narcolepsy symptoms</article-title>. <source><italic toggle="yes">Neurology</italic></source>. <year>2017</year>;<volume>88</volume>(<issue>14</issue>):<fpage>1358</fpage>–<lpage>1365</lpage>. doi:<pub-id pub-id-type="doi">10.1212/wnl.0000000000003787</pub-id><pub-id pub-id-type="pmid">28258080</pub-id></mixed-citation>
      </ref>
      <ref id="cit0115">
        <label>115.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Wang</surname>
<given-names>YG</given-names></string-name>, <string-name><surname>Benmedjahed</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lambert</surname>
<given-names>J</given-names></string-name>, et al. <article-title>Assessing narcolepsy with cataplexy in children and adolescents: development of a cataplexy diary and the ESS-CHAD</article-title>. <source><italic toggle="yes">Nat Sci Sleep</italic></source>. <year>2017</year>;<volume>9</volume>:<fpage>201</fpage>–<lpage>211</lpage>. doi:<pub-id pub-id-type="doi">10.2147/nss.s140143</pub-id><pub-id pub-id-type="pmid">28860883</pub-id></mixed-citation>
      </ref>
      <ref id="cit0116">
        <label>116.</label>
        <mixed-citation publication-type="journal"><string-name><surname>Plazzi</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ruoff</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lecendreux</surname>
<given-names>M</given-names></string-name>, et al. <article-title>Treatment of paediatric narcolepsy with sodium oxybate: a double-blind, placebo-controlled, randomised-withdrawal multicentre study and open-label investigation</article-title>. <source><italic toggle="yes">Lancet Child Adolesc Heal</italic></source>. <year>2018</year>;<volume>2</volume>(<issue>7</issue>):<fpage>483</fpage>–<lpage>494</lpage>. doi:<pub-id pub-id-type="doi">10.1016/s2352-4642(18)30133-0</pub-id></mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
